

# Ca<sup>2+</sup> fluxes and cancer

Saverio Marchi<sup>1</sup>, Carlotta Giorgi<sup>2</sup>, Lorenzo Galluzzi<sup>3,4,5,6,7,\*</sup> and Paolo Pinton<sup>2,\*</sup>

<sup>1</sup>Department of Clinical and Molecular Sciences, Marche Polytechnic University, Ancona, Italy; <sup>2</sup>Department of Medical Sciences, Surgery and Experimental Medicine, Section of Pathology, Oncology and Experimental Biology, Laboratory for Technologies of Advanced Therapies (LTTA), University of Ferrara, Ferrara, Italy; <sup>3</sup>Department of Radiation Oncology, Weill Cornell Medical College, New York, NY, USA; <sup>4</sup>Sandra and Edward Meyer Cancer Center, New York, NY, USA; <sup>5</sup>Caryl and Israel Englander Institute for Precision Medicine, New York, NY, USA; <sup>6</sup>Department of Dermatology, Yale School of Medicine, New Haven, CT, USA; <sup>7</sup>Université de Paris, Paris, France.

\*Correspondence to Paolo Pinton (paolo.pinton@unife.it) or Lorenzo Galluzzi

---

**Running title:** Calcium transport and cancer

**Keywords:** IP<sub>3</sub>R, MCU complex; mitochondrial permeability transition; ORAI; store-operated calcium entry; TRP channels.

**Disclosures:** LG has received consulting fees from Astra Zeneca, Boehringer Ingelheim, Inzen and the Luke Heller TECPR2 Foundation, and he is member of Scientific Advisory Committees for Boehringer Ingelheim and OmniSEQ. The other authors declare no conflicts of interest.

## **Abstract**

Ca<sup>2+</sup> ions are key second messengers in both excitable and non-excitable cells. Owing to the rather pleiotropic nature of Ca<sup>2+</sup> transporters and other Ca<sup>2+</sup>-binding proteins, however, Ca<sup>2+</sup> signaling has attracted limited attention as potential target for anticancer therapy. Here, we discuss cancer-associated alterations of Ca<sup>2+</sup> fluxes at specific organelles as we identify novel candidates for the development of drugs that selectively target Ca<sup>2+</sup> signaling in malignant cells.

## Introduction

Historically, the molecular machinery that regulates intracellular calcium ( $\text{Ca}^{2+}$ ) fluxes has attracted limited attention as a potential target for cancer therapy, largely reflecting the fact that  $\text{Ca}^{2+}$  signaling was viewed as uniform across non-excitable cells (Berridge et al., 2000), and hence was considered incompatible with the development of selective agents. However, the role of  $\text{Ca}^{2+}$  in malignant transformation, tumor progression and response to treatment has been considerably re-evaluated over the past decade (Monteith et al., 2017). Such a reappraisal has originated not only from structural and functional studies that enabled the development of therapeutic agents targeting  $\text{Ca}^{2+}$  signaling for non-malignant disorders affecting excitable cells (*e.g.*, arrhythmias, epilepsy) (Frishman, 2007; Weiss and Zamponi, 2019), but also from the ever-increasing deconvolution of intracellular  $\text{Ca}^{2+}$  fluxes as spatially restricted processes that can be targeted therapeutically. Thus, it is now clear that the molecular machinery that controls intracellular  $\text{Ca}^{2+}$  signaling in malignant cells is altered as a consequence of changes in expression levels and/or post-translational modifications in its key components or their interactors. Such defects enable malignant transformation, support tumor progression and play a key role in sensitivity to treatment, *de facto* standing out as potential target for the development of targeted therapeutics.

In this Review, we critically discuss the molecular mechanisms through which alterations of  $\text{Ca}^{2+}$  fluxes at specific organelles impact on multiple aspects of the malignant phenotype, including aberrant proliferation, resistance to cell death and metastatic dissemination, with a focus on the possibility to harness such defects for therapeutic purposes. In line with this focus,  $\text{Ca}^{2+}$ -buffering proteins are not discussed herein, although they undoubtedly impact multiple aspects of oncogenesis (Schwaller, 2020).

## Global Ca<sup>2+</sup> homeostasis in normal cells

Cells need to maintain extremely low cytosolic Ca<sup>2+</sup> levels (~100 nM), hence establishing a 10- to 15,000-fold gradient with the extracellular milieu (where Ca<sup>2+</sup> concentration is approx. 1-1.5 mM). Although the original evolutionary advantage of such a gradient was the avoidance of potentially cytotoxic Ca<sup>2+</sup>-phosphate precipitates, a variety of functions have evolved around such a compartmentalized source of electrochemical energy, including intracellular signal transduction as well metabolite transport across membranes (Bootman and Bultynck, 2020; Chen et al., 2020).

Two main ATP-dependent systems extrude Ca<sup>2+</sup> from the cytosol of mammalian cells: plasma membrane Ca<sup>2+</sup> ATPases (PMCA), which expel Ca<sup>2+</sup> to the extracellular space, and sarcoendoplasmic reticular Ca<sup>2+</sup> ATPases (SERCAs), which accumulate it within the endoplasmic reticulum (ER). Moreover, secretory pathway Ca<sup>2+</sup> ATPases (SPCAs) promote Ca<sup>2+</sup> accumulation within the Golgi apparatus (GA), while other organelles such as lysosomes can store Ca<sup>2+</sup>, either as a functional consequence of vesicular trafficking from the extracellular Ca<sup>2+</sup>-rich milieu (*e.g.*, endocytosis) (Galluzzi and Green, 2019) or (at least theoretically) through an hitherto elusive Ca<sup>2+</sup>/H<sup>+</sup> exchanger (Melchionda et al., 2016). That said, these latter intracellular Ca<sup>2+</sup> stores are quantitatively limited as compared to the ER (Yang et al., 2019).

Cytosolic Ca<sup>2+</sup> signaling (during which cytosolic Ca<sup>2+</sup> concentrations reach 1-2 μM) can be driven by both intracellular and extracellular stores. One of the most common pathways for mammalian cells to evoke Ca<sup>2+</sup> signaling is initiated by ligand-engaged G-protein coupled receptors (Jain et al., 2018), causing the synthesis of 1,4,5-inositol trisphosphate (IP<sub>3</sub>) and IP<sub>3</sub>-dependent opening of Ca<sup>2+</sup> channels of the IP<sub>3</sub> receptor (IP<sub>3</sub>R) family at the ER membrane (Prole and Taylor, 2019). Alternatively, IP<sub>3</sub>R opening can be initiated by receptor tyrosine kinase signaling and consequent activation of phospholipase C gamma 1 (PLCG1), at least in

some cells (Lundgren et al., 2012). Moreover,  $\text{Ca}^{2+}$  ions can accumulate in cytosol upon the production of reactive oxygen species (ROS) or phosphatidylinositol 3,5-bisphosphate ( $\text{PI}(3,5)\text{P}_2$ ) and consequent opening of the ROS- and  $\text{PI}(3,5)\text{P}_2$ -sensitive lysosomal  $\text{Ca}^{2+}$  channels mucolipin 1 (MCOLN1, also known as TRPML1) (Zhang et al., 2016) and two pore segment channel 2 (TPCN2) (Li et al., 2019).

Extracellular  $\text{Ca}^{2+}$  ions (which are the predominant source for cytosolic  $\text{Ca}^{2+}$  signaling in excitable cells) (Moran et al., 2011) can access the cytosol via a variety of non-voltage-gated non-selective cation channels, including members of the transient receptor potential (TRP) superfamily (which also include MCOLN1) (Venkatachalam and Montell, 2007), and through numerous voltage-dependent  $\text{Ca}^{2+}$  channels, including L-, R-, N-, P/Q- and T-type channels (Catterall, 2011). Although voltage-dependent  $\text{Ca}^{2+}$  channels are widely expressed by excitable cells, they have also been detected in non-excitable (including malignant) cells (Phan et al., 2017). Of note, cytosolic  $\text{Ca}^{2+}$  fluxes driven by extracellular and intracellular stores are not mutually exclusive but interconnected and highly coordinated. For instance, excitatory  $\text{Ca}^{2+}$  signaling is initiated by plasma membrane (PM)  $\text{Ca}^{2+}$  channels but sustained by reticular  $\text{Ca}^{2+}$  (Roderick et al., 2003). Along similar lines,  $\text{Ca}^{2+}$  mobilization from intracellular stores in non-excitable cells is generally followed by PMCA-dependent  $\text{Ca}^{2+}$  extrusion to the extracellular space (Berridge et al., 2003).

Importantly, extracellular  $\text{Ca}^{2+}$  is required to replete intracellular stores in both excitable and non-excitable cells, reflecting the ability of PMCAs to translocate  $\text{Ca}^{2+}$  across membranes faster than SERCAs and SPCAs (Bootman and Bultynck, 2020). In this setting,  $\text{Ca}^{2+}$ -depleted cells initiate a slow  $\text{Ca}^{2+}$  flux from the extracellular space to the ER lumen commonly known as store-operated  $\text{Ca}^{2+}$  entry (SOCE). At the molecular level, SOCE is mediated by specific members of the ORAI calcium release-activated calcium modulator (ORAI) family, including ORAI calcium release-activated calcium modulator 1 (ORAI1) and ORAI calcium release-

activated calcium modulator 1 (ORAI3) (Derler et al., 2016). These PM  $\text{Ca}^{2+}$  channels relocate to PM-ER junctions upon oligomerization of members of the stromal interaction molecule (STIM) family. Such an interaction generates so-called  $\text{Ca}^{2+}$  release-activated  $\text{Ca}^{2+}$  (CRAC) channels, which enable the accumulation of cytosolic  $\text{Ca}^{2+}$  ions available for uptake by SERCAs (Derler et al., 2016). Mitochondria are also recruited to neo-formed CRAC channels, where they have been proposed to mediate hitherto unclear regulatory functions (Malli and Graier, 2017). Of note, ORAI1 and ORAI3 can also form channels that support arachidonate-driven  $\text{Ca}^{2+}$  entry, an activity that does not depend on STIM1 (Thompson et al., 2013).

The contribution of mitochondria to intracellular  $\text{Ca}^{2+}$  homeostasis goes way beyond their potential SOCE-regulatory activity. Baseline mitochondrial  $\text{Ca}^{2+}$  levels resemble their cytosolic counterparts (Giorgi et al., 2018b), but the capacity of the mitochondrial network to accumulate  $\text{Ca}^{2+}$  upon release from the ER (or entry from the extracellular space) is 10 times higher than that of the cytosol (Giorgi et al., 2018b). Such a capacity, which affects not only mitochondrial metabolism but also  $\text{Ca}^{2+}$  signaling at extramitochondrial sites and various other cellular processes (*e.g.*, regulated cell death) is commonly referred to as  $\text{Ca}^{2+}$  buffering (Giorgi et al., 2018b).  $\text{Ca}^{2+}$  ions readily cross the outer mitochondrial membrane (OMM) via members of the voltage-dependent anion channel (VDAC) family including VDAC1, VDAC2 and VDAC3 (De Stefani et al., 2012; Shimizu et al., 2015), and then accumulate in the mitochondrial matrix via the mitochondrial calcium uniporter (MCU), a supramolecular complex under positive and negative regulation by mitochondrial calcium uniporter regulator 1 (MCUR1) and mitochondrial calcium uptake 1 (MICU1), respectively (Kamer and Mootha, 2015; Mallilankaraman et al., 2012a; Mallilankaraman et al., 2012b). Mitochondria extrude  $\text{Ca}^{2+}$  via the  $\text{Na}^+/\text{Ca}^{2+}$  exchanger solute carrier family 8 member B1 (SLC8B1, best known as NCLX) (Palty et al., 2010) and a  $\text{H}^+/\text{Ca}^{2+}$  antiporter, whose molecular nature remains unclear.

A potential (but hitherto unconfirmed) candidate for this latter activity is leucine zipper and EF-hand containing transmembrane protein 1 (LETM1) (Jiang et al., 2009).

In summary, normal cells regulate intracellular  $\text{Ca}^{2+}$  fluxes via a highly interconnected machinery that operates at multiple organelles to allow  $\text{Ca}^{2+}$  ions to act as second messengers while preventing their potential cytotoxicity (**Figure 1**). Malignant cells display a variety of defects in such a machinery (Roberts-Thomson et al., 2019), which can be harnessed for the development of novel therapeutic agents, as discussed below.

## Plasma membrane Ca<sup>2+</sup> transporters and cancer

One of the main hallmarks of malignant cells is their ability to boost ROS signaling in support of metabolism, proliferation and metastatic dissemination while evading the cytotoxicity of ROS overgeneration (Pervaiz, 2018). Besides an extensive metabolic rewiring that support the generation of endogenous antioxidants like glutathione (Galluzzi et al., 2013; Gorrini et al., 2013), alterations of Ca<sup>2+</sup> signaling at mitochondria (see below) and the PM are largely responsible for this feature. Indeed, while mitochondrial Ca<sup>2+</sup> promotes ROS generation (see below), the accumulation of ROS at the PM imposes post-translational modifications on some PM Ca<sup>2+</sup> channels that promote Ca<sup>2+</sup> entry to boost antioxidant defenses (Takahashi et al., 2018).

Transient receptor potential cation channel subfamily A member 1 (TRPA1) is generally expressed in neurons but is ectopically upregulated in breast and lung tumors, where it mediates Ca<sup>2+</sup> influx across the PM in response to pro-oxidants, including ROS-generating chemotherapeutics, *de facto* supporting cell survival (Takahashi et al., 2018). At least in part, the ability of TRPA1 to favor chemoresistance originates from the Ca<sup>2+</sup>-dependent binding of calmodulin 1 (CALM1) to protein tyrosine kinase 2 beta (PTK2B, also known as PYK2), ultimately resulting in the upregulation of the cytoprotective factor MCL1 apoptosis regulator, BCL2 family member (MCL1) (Galluzzi et al.; Porporato et al., 2018; Takahashi et al., 2018). At least in some settings, such a pro-survival effect is compromised by ROS-dependent S-glutathionylation of stromal interaction molecule 1 (STIM1), resulting in persistent Ca<sup>2+</sup> entry via SOCE, mitochondrial permeability transition (MPT) and ultimately cell death (Hawkins et al., 2010).

Importantly, Ca<sup>2+</sup>-bound CALM1 directly interacts with (hence regulating the activity of) TRPA1 (and other TRP family members) (Hasan and Zhang, 2018). However, CALM1

potentiates TRPA1 at moderate  $\text{Ca}^{2+}$  concentrations, whereas it has inhibitory effects in response to robust elevation in  $\text{Ca}^{2+}$  levels (Zurborg et al., 2007). These data are incompatible with the ability of cancer cells to display chronic TRPA1 hyperactivation despite increased cytosolic  $\text{Ca}^{2+}$  concentrations. At least theoretically, such an apparent discrepancy may originate from differences in the nature of  $\text{Ca}^{2+}$  signals and/or  $\text{Ca}^{2+}$ -buffering systems operating in malignant *versus* normal cells. Indeed, both pro-oxidants like  $\text{H}_2\text{O}_2$  and chemotherapeutics (*i.e.*, carboplatin) trigger slow and moderate oscillations in cytosolic  $\text{Ca}^{2+}$  levels, which differ from those generated by TRPA1 activating stimuli (like mustard oil), but may resemble those originated from  $\text{Ca}^{2+}$  pulses by uncaging of 1-(4,5-dimethoxy-2-nitrophenyl)-EDTA, which induces TRPA1 potentiation without inactivation (Wang et al., 2008). These observations support the potential utility of agents that would selectively inhibit TRPA1 or target the CALM1  $\rightarrow$  TRPA1 axis in support to common chemotherapeutics that compromise antioxidant defenses in cancer cells.

*TRPA1* is upregulated in breast and lung tumors in which the master antioxidant regulator nuclear factor, erythroid 2 like 2 (NFE2L2, best known as NRF2) is hyperactive (Takahashi et al., 2018), which orchestrates ROS resistance via canonical and non-canonical (*i.e.*, via TRPA1) mechanisms. The oncogenic activity of NRF2 is also associated with other TRP channels. In particular,  $\text{Ca}^{2+}$  entry through the redox-sensitive channel transient receptor potential cation channel subfamily M member 2 (TRPM2) drives NRF2 activation and consequent upregulation of various antioxidant enzymes and IQ motif containing GTPase activating protein 1 (IQGAP1), a  $\text{Ca}^{2+}$ -dependent modulator of NRF2 stability (Bao et al., 2019). Importantly, TRPA1 and TRPM2 are often co-expressed in malignant lesions (Takahashi et al., 2018), suggesting a synergistic role of different TRP members in defining a specific malignant phenotype.

Other TRP channels are frequently overexpressed in human tumors, including transient receptor potential cation channel subfamily M member 3 (TRPM3) (Hall et al., 2014), transient receptor potential cation channel subfamily C member 1 (TRPC1) (Azimi et al., 2017), transient receptor potential cation channel subfamily C member 6 (TRPC6) (Guilbert et al., 2008), transient receptor potential cation channel subfamily V member 4 (TRPV4) (Peters et al., 2017), and transient receptor potential cation channel subfamily V member 6 (TRPV6) (Fixemer et al., 2003). Moreover, transient receptor potential cation channel subfamily M member 7 (TRPM7) and transient receptor potential cation channel subfamily V member 2 (TRPV2) appear to be upregulated at sites of metastatic dissemination (Canales et al., 2019). Mechanistically, TRPM3 has been shown to promote the progression of clear cell renal cell carcinomas by stimulating autophagy (an evolutionary conserved cytoprotective mechanism) (Galluzzi et al., 2018c) via calcium/calmodulin dependent protein kinase kinase 2 (CAMMK2) (Hall et al., 2014). Conversely, TRPM7 is the main TRP channel involved in the generation of short-lived  $\text{Ca}^{2+}$  flickers that drive cancer cell migration (Wei et al., 2009). Finally, elevated cytosolic  $\text{Ca}^{2+}$  levels correlate with increased secretion of matrix metalloproteinases by cancer cells (Monet et al., 2010; Rybarczyk et al., 2017), *de facto* favoring a remodeling of the local microenvironment in support of metastatic dissemination. Importantly, non-transformed cells experience TRP activation rapidly undergo cytosolic  $\text{Ca}^{2+}$  and cell death (Shapovalov et al., 2011). Thus, malignant cells must acquire additional features that allow them to control the amplitude and kinetics of  $\text{Ca}^{2+}$  fluxes and hence harness the beneficial effects of  $\text{Ca}^{2+}$  signaling while avoid its potential cytotoxicity. Besides a superior resistance to cell death induction (Hanahan and Weinberg, 2011), these changes include (but are not limited to) an increased mitochondrial capacity for  $\text{Ca}^{2+}$  buffering (see below).

SOCE is also frequently altered in malignant cells, although defining the contribution of SOCE defects to malignant transformation, tumor progression or sensitivity to treatment is complex,

given the multifactorial nature of the CRAC channel. Nonetheless, upregulation of STIM1 alone or together with ORAI1 correlates with increased migratory capacity, metastatic dissemination and poor overall survival in different human tumors (Yang et al., 2009). Mechanistically, this ensues the establishment of oscillatory  $\text{Ca}^{2+}$  signals at specialized PM areas that enable the invadopodium formation, extracellular matrix degradation (Sun et al., 2014), and PYK2 activation (Chen et al., 2011).

Polarized SOCE in malignant cells is also driven by the interaction of ORAI1 with potassium calcium-activated channel subfamily N member 3 (KCNN3) at specific glycolipoprotein- and cholesterol-rich microdomains of the PM termed lipid rafts (Chantome et al., 2013). Such as polarization appears to be controlled (at least in part) by the microtubule system, under regulation by the tubulin-modifying enzyme histone deacetylase 6 (HDAC6) (Chen et al., 2013). In support of this notion, SOCE favors cellular migration when adhesion to the matrix is weak (*i.e.*, in metastatic cells displaying considerable microtubular rewiring), whereas it inhibits migration when adhesion is strong (*i.e.*, in normal cells) (Tsai et al., 2014). Altogether, these observations identify a key role for SOCE remodeling in tumor progression. Further supporting this notion, gain-of-function *ORAI1* mutations causing constitutive  $\text{Ca}^{2+}$  influx and  $\text{Ca}^{2+}$ -dependent activation of nuclear factor of activated T cells 1 (NFATC1) have been associated with cancer (Frischauf et al., 2017). Moreover, SOCE inhibition by pharmacological agents limits the migration and proliferation of cultured human breast cancer cells (Azimi et al., 2018).

Apparently at odds with this, ORAI1 downregulation and consequent SOCE abolition protects prostate cancer cells from cell death induced by thapsigargin, which evokes a sustained  $\text{Ca}^{2+}$  influx to the cytoplasm (Flourakis et al., 2010). Similar observations have been obtained in colorectal cancer cells harboring oncogenic *KRAS* mutations, although in this case SOCE inhibition originated from decreased STIM1 levels (Pierro et al., 2018). Thus, the

downregulation of various components of CRAC channels may promote the resistance of cancer cells to stressors that favor  $\text{Ca}^{2+}$  influx, including hypoxia.

Taken together, these observations that cancer cells can take advantage of both SOCE activation and inhibition, depending on contextual factors including the configuration of the molecular machinery for cell death. In some cases, such as advanced, androgen-independent prostate cancer, an alternative ORAI variant, *i.e.*, ORAI3, has been shown to form heteromultimeric complexes with ORAI1 to ensure store-independent arachidonic acid-regulated  $\text{Ca}^{2+}$  entry in the context of conventional, ORAI1-dependent SOCE inhibition (Dubois et al., 2014). Altogether, these changes ensure oscillatory  $\text{Ca}^{2+}$  waves that promote tumor progression and support antioxidant defenses (see above), along with cell death resistance. Of note, ORAI3 mediates oncogenic functions also in the mammary tissue (Hasna et al., 2018; Motiani et al., 2010; Motiani et al., 2013), and increased *ORAI3/ORAI1* expression ratio correlates with poor prognosis in colorectal cancer patients (Ibrahim et al., 2019). Thus, while ORAI3 stands out as a prominent candidate for the development of therapeutic agents specific for cancer cells, pharmacological inhibition of conventional SOCE may be detrimental as (1) it would limit the activity of some chemotherapeutics that trigger ER stress (*e.g.*, cisplatin) (Gualdani et al., 2019), and (2) it would compromise anticancer immune responses by  $\text{CD8}^+$  T cells, which strictly rely on SOCE (Weidinger et al., 2013).

Thus, multiple steps of the oncogenic cascade are influenced by deregulation of  $\text{Ca}^{2+}$  fluxes at the PM (**Figure 2**), but targeting such alterations remain challenging given the pleiotropism of the system, perhaps with the sole exception of ORAI3. An alternative approach that remains to be pursued is the development of agents specific for mutant ORAI1, although they would only be useful for cancers bearing *ORAI1* mutations.

## Oncogenic Ca<sup>2+</sup> dynamics at the endoplasmic reticulum

Alterations in reticular Ca<sup>2+</sup> fluxes affect Ca<sup>2+</sup> homeostasis at large, not only because the ER is the major cellular store for Ca<sup>2+</sup>, but also because Ca<sup>2+</sup> levels at extrareticular sites strictly depend on reticular Ca<sup>2+</sup> dynamics (Giorgi et al., 2018a). Of note, specialized regions of the ER that are preferentially juxtaposed to mitochondria – the so-called mitochondria-associated ER membranes (MAMs) (**Box 1**) – are sites for preferential Ca<sup>2+</sup> transfer to mitochondria (Wu et al., 2018). Reflecting the key role of mitochondrial Ca<sup>2+</sup> in the control of proliferation, metabolism and cell death (see below), several oncogenic and oncosuppressive proteins strategically localize to MAMs to regulate cell fate by interfering with ER Ca<sup>2+</sup> fluxes (Marchi et al., 2014).

The precise role of ER Ca<sup>2+</sup> uptake in oncogenesis and tumor progression is difficult to ascertain as SERCAs are encoded by 3 different genes (*i.e.*, *ATP2A1*, *ATP2A2*, *ATP2A3*) in 14 splicing variants, and the downregulation of specific transcript is generally associated with compensatory mechanisms (Arbajian et al., 2011). In line with this notion ATPase sarcoplasmic/endoplasmic reticulum Ca<sup>2+</sup> transporting 3 (*ATP2A3*, best known as *SERCA3*) expression decrease during colorectal carcinogenesis (Brouland et al., 2005), but reticular Ca<sup>2+</sup> levels appear to remain unaffected, potentially upon compensatory *ATP2A2* (best known as *SERCA2*) upregulation (Fan et al., 2014).

Initial interest in SERCAs as target for anticancer therapy stemmed from the highly cytotoxic, but virtually unselective, activity of the pan-SERCA inhibitor thapsigargin (Lytton et al., 1991). To circumvent limited selectivity, thapsigargin has been engineered for activation by folate hydrolase 1 (*FOLH1*, also known as *PSMA*), which is abundant in the microenvironment of some malignant (but not normal) tissues (Denmeade et al., 2012). Moreover, it seems that malignant cells driven by *NOTCH* or *WNT* signaling are particularly sensitive to low-dose

thapsigargin (Roti et al., 2013; Suisse and Treisman, 2019), which may open a therapeutic window. However, while the abolition of reticular  $\text{Ca}^{2+}$  uptake is highly cytotoxic, lowered  $\text{Ca}^{2+}$  concentrations may support tumor progression. In line with this notion, heterozygous loss-of-function mutations in *Atp2a2* predispose mice to gastric carcinogenesis (Prasad et al., 2005), and mutations in each of the SERCA-coding genes have been documented in a variety of tumors including head and neck cancer (Stransky et al., 2011). Moreover, chemoresistance supported by tumor protein p53 (*TP53*) mutations or thioredoxin-related transmembrane protein 1 (TMX1) downregulation is accompanied by inhibition of SERCA activity (Giorgi et al., 2015; Raturi et al., 2016). Finally, truncated ATPase sarcoplasmic/endoplasmic reticulum  $\text{Ca}^{2+}$  transporting 1 (ATP2A1, best known as SERCA1) splice variants not only reduce reticular  $\text{Ca}^{2+}$  levels at baseline, but also favor  $\text{Ca}^{2+}$  leakage, which supports at least some degree of mitochondrial signaling (Chami et al., 2001). Thus, genetic defects in various SERCAs appear to endow (pre-)malignant cells with a dual advantage: protection from  $\text{Ca}^{2+}$  overload-driven cell death and generation of spontaneous  $\text{Ca}^{2+}$  oscillations that promote mitochondrial activity (see below).

Similar oncogenic functions have been attributed to the antiapoptotic proteins BCL2 apoptosis regulator (BCL2) and BCL2 like 1 (BCL2L21, best known as BCL-X<sub>L</sub>), although these may operate on reticular  $\text{Ca}^{2+}$  efflux via IP<sub>3</sub>Rs (Pinton et al., 2000; White et al., 2005). In this context, inositol 1,4,5-trisphosphate receptor type 3 (ITPR3, best known as IP<sub>3</sub>R3) and ITPR2 (best known as IP<sub>3</sub>R2) may play a predominant role as compared to ITPR1 (best known as IP<sub>3</sub>R1), at least potentially reflecting their elevated capacity to transmit  $\text{Ca}^{2+}$  signals to mitochondria (Bartok et al., 2019; Mendes et al., 2005; Sun et al., 2019). However, whether BCL2 and other antiapoptotic Bcl-2 proteins limit agonist-induced  $\text{Ca}^{2+}$  release through IP<sub>3</sub>Rs by inhibiting them (Ivanova et al., 2019; Rong et al., 2009), promoting some degree of activation at baseline by increasing the sensitivity to IP<sub>3</sub> (Eckenrode et al., 2010; White et al.,

2005), or supporting a cytoprotective  $\text{Ca}^{2+}$  leak from the ER via other mechanisms (Bassik et al., 2004; Palmer et al., 2004; Pinton et al., 2000; Pinton et al., 2001) remains to be clarified. At least in part, these apparently contrasting observations may relate to the ability of both pro- and anti-apoptotic Bcl-2 family members to regulate VDAC opening (Chong et al., 2020; Shimizu et al., 1999; Tajeddine et al., 2008) and the highly divergent expression of these regulators of apoptosis in cells from different tissues or tumor types, ultimately resulting in different priming of the apoptotic system at mitochondria (Potter and Letai, 2016).

Consistent with this, multiple MAM-resident oncogenic proteins other than BCL2 and BCL-X<sub>L</sub>, such as promyelocytic leukemia (PML), AKT serine/threonine kinase 1 (AKT1) and KRAS<sup>G13D</sup> inhibit IP<sub>3</sub>R3 at MAMs to promote tumor progression (Betz et al., 2013; Bononi et al., 2017; Giorgi et al., 2010; Kuchay et al., 2017; Marchi et al., 2012; Pierro et al., 2014). However, IP<sub>3</sub>R3 upregulation has also been attributed oncogenic roles in some tissues, especially the gastric epithelium, bile ducts and liver (Guerra et al., 2019; Mangla et al., 2020; Ueasilamongkol et al., 2019). In these settings, additional mechanisms must be at play to inhibit cell death, as transient IP<sub>3</sub>R3 overexpression is generally sufficient to kill both normal and cancer cells (Guerra et al., 2019; Ueasilamongkol et al., 2019). Although the precise antiapoptotic pathways supporting oncogenesis in IP<sub>3</sub>R3-overexpressing cells remain to be elucidated, it is tempting to invoke defects in MPT, the major cell death routine triggered by  $\text{Ca}^{2+}$  overload (Galluzzi et al., 2018b). Testing the responsiveness of IP<sub>3</sub>R3-overexpressing cancer cells to hydrogen peroxide (another trigger of MPT) will provide additional insights into this possibility.

Altogether, these observations exemplify how SERCA and IP<sub>3</sub>R defects can contribute to oncogenesis and tumor progression (**Figure 3**). In this setting, while activation of  $\text{Ca}^{2+}$  release may cause the death (or at least increase the chemosensitivity) of cancer cells with intact ER

stores, inhibition of  $\text{Ca}^{2+}$  efflux stands out as potential strategy to inhibit malignant cells that rely on constitutive  $\text{Ca}^{2+}$  to mitochondria for metabolism and proliferation, as discussed below.

## **Mitochondrial Ca<sup>2+</sup> homeostasis and cancer progression**

Mitochondrial Ca<sup>2+</sup> accumulation upon cytosolic Ca<sup>2+</sup> signaling regulates intra- and extramitochondrial metabolism and has a major influence on the propensity of cells to undergo cell death via MPT (Bonora et al., 2019). Cancer cells of different histological derivation overexpress channels of the VDAC family (which enable Ca<sup>2+</sup> to cross the OMM) (Mazure, 2017), as well as MCU, the pore-forming unit of the complex responsible for Ca<sup>2+</sup> accumulation in the mitochondrial matrix (Marchi et al., 2019b; Vultur et al., 2018). Although such alterations would theoretically increase the propensity of cancer cells to undergo MPT and die in response to a variety of stressors, mitochondria from malignant cells are highly protected from permeabilization as they contain increased levels of MCL1 and other anti-apoptotic proteins of the Bcl-2 family (Singh et al., 2019). Such an increased capacity for Ca<sup>2+</sup> uptake boosts mitochondrial respiration by favoring the activity of multiple dehydrogenases involved in the tricarboxylic acid cycle (TCA), ultimately resulting in enhanced ATP and ROS production (Denton, 2009). At least in part, accrued ROS synthesis as driven by Ca<sup>2+</sup> involves specialized MAM regions coupling cytosolic Ca<sup>2+</sup> oscillations to H<sub>2</sub>O<sub>2</sub> generation in nanodomains localized to mitochondrial cristae (Booth et al., 2016).

In line with these notions, MCU levels in malignant cells positively correlate with mitochondrial Ca<sup>2+</sup> uptake, ROS production, migratory capacity and propensity for metastatic dissemination. Besides improved ATP availability, the ROS-driven activation of hypoxia inducible factor 1 subunit alpha (HIF1A), a transcription factor that promotes glycolysis and favors local immunosuppression (Choudhry and Harris, 2018; Vitale et al., 2019), as well as the ROS-dependent secretion of the pro-metastatic enzyme matrix metalloproteinase 2 (MMP2) (Conlon and Murray, 2019). play a major role in the ability of mitochondrial Ca<sup>2+</sup> to drive tumor progression (Ren et al., 2017; Tosatto et al., 2016). Ca<sup>2+</sup>-dependent ROS generation also occurs when MICU1 is downregulated, reflecting the physiological role of MICU1 as MCU

inhibitor (Csordas et al., 2013; Mallilankaraman et al., 2012b). Accordingly, reduced MICU1 levels and high MCU/MICU1 ratios have been associated with poor disease outcome in patients with hepatocellular carcinoma (Ren et al., 2017) and breast cancer (Curry et al., 2013), respectively. Of note, MCU, whose conductivity for  $\text{Ca}^{2+}$  is positively regulated by ROS-driven S-glutathionylation (Dong et al., 2017), also controls cell cycle progression by generating spontaneous mitochondrial  $\text{Ca}^{2+}$  transients that coordinate mitotic entry in support to proliferation (Koval et al., 2019; Zhao et al., 2019), which identifies yet another mechanism for ROS-driven alterations in mitochondrial  $\text{Ca}^{2+}$  fluxes to support tumor progression.

That said, some tumors display reduced MCU or high MICU1 levels, which underlies (at least some degree of) cell death resistance (Chakraborty et al., 2017; Hong et al., 2017; Marchi et al., 2013). In this setting, restoring normal mitochondrial  $\text{Ca}^{2+}$  uptake results in overt cytotoxicity or sensitization to conventional therapeutic agents (Chakraborty et al., 2017; Marchi et al., 2013). Although the reasons why some cancer cells acquire diametrically opposed alterations in mitochondrial  $\text{Ca}^{2+}$  dynamics remain to be clarified, it is tempting to invoke the extraordinary metabolic and functional flexibility that generally accompanies malignant transformation as a main factor. Thus, while cancer cells that synthesize ATP by glycolysis may achieve increased resistance to cell death by MCU inhibition (via MCU downregulation or MICU1 upregulation), malignant cells that prevalently rely on mitochondrial respiration for ATP synthesis are expected to require a hyperactive MCU complex (upon MCU upregulation or MICU1 downregulation), calling for the establishment of alternative cytoprotective pathways.

Consistent with this view, highly glycolytic ovarian cancer cells exhibit high MICU1 expression, reduced mitochondrial  $\text{Ca}^{2+}$  levels and resistance to cisplatin (Chakraborty et al., 2017). Cytoprotective alterations potentially at work in malignant cells that rely on mitochondrial  $\text{Ca}^{2+}$  signaling for bioenergetic metabolism and proliferation include reinforced

antioxidant defenses (Bansal and Simon, 2018), as well as endogenous MPT inhibition (Antony et al., 2016; Marchi et al., 2019c). Notably, the oncogenic protein AKT1 and the oncosuppressor TP53, whose ability to inhibit or drive cell death, respectively, has been linked to  $\text{Ca}^{2+}$  regulation, control MPT by phosphorylating (AKT1) or physically interacting with (TP53) the key MPT regulator peptidylprolyl isomerase F (PPIF, best known as CYPD) (Ghosh et al., 2015; Vaseva et al., 2012). Moreover, AKT1-expressing tumors require high mitochondrial  $\text{Ca}^{2+}$  and ROS production at baseline to proliferate, largely as a result of phosphorylation-dependent MICU1 inhibition (Marchi et al., 2019a). Altogether, these findings delineate a complex mechanism whereby mitochondrial  $\text{Ca}^{2+}$  signaling and cell death resistance co-evolve with metabolic alterations in the context of tumor progression.

The oncogenic activity of MCUR1 provides additional insights in the role of mitochondrial  $\text{Ca}^{2+}$  in cancer. In line with the ability of MCUR1 to positively regulate MCU activity, MCUR1 expression levels positively correlate with mitochondrial  $\text{Ca}^{2+}$  accumulation (Mallilankaraman et al., 2012a). In hepatocellular carcinoma cells, MCUR1 is strongly upregulated in the context of ROS overproduction, resulting in ROS-dependent TP53 degradation and consequent resistance to cell death (Ren et al., 2018). In this context, antioxidant defenses are also elevated downstream of NRF2 activation, which further lowers cellular susceptibility to cell death in the presence of increased ROS levels that sustain proliferation (Jin et al., 2019). That said, MCUR1 has also been suggested to operate as an assembly factor for respiratory complex IV (Paupe et al., 2015). In this scenario, the correlation of MCUR1 levels with mitochondrial  $\text{Ca}^{2+}$  uptake and ROS production may reflect the impact of MCUR1 on oxidative phosphorylation, suggesting an alternative,  $\text{Ca}^{2+}$ -independent mechanism through which MCUR1 promotes tumor progression. This possibility, however, remains to be experimentally verified.

While the impact of MCU complex activity on oncogenesis has been investigated by multiple groups, the impact of other mitochondrial  $\text{Ca}^{2+}$  transporters in malignant transformation, tumor

progression and response to therapy remains obscure. NCLX controls SOCE via a sophisticated redox circuitry (Ben-Kasus Nissim et al., 2017), but its role in cancer cell proliferation, cell death and migration is unclear. The impact of VDACs on the biology of (pre-)malignant cells appears to (1) be independent of their permeability to  $\text{Ca}^{2+}$  ions, and (2) display considerable variability. Indeed, VDACs support tumor progression as integral parts of the molecular machinery that exchanges key metabolites (e.g., ADP, ATP) across the OMM (Mazure, 2017), but also operate as a key mediator of MPT, *de facto* favoring the death of (pre-)malignant cells exposed to chemotherapy (Tajeddine et al., 2008). LETM1 is markedly overexpressed in various neoplasms, and it reportedly supports cancer cell survival and metabolic fitness (Piao et al., 2009), but it remains unclear whether these effects depend on  $\text{Ca}^{2+}$  signaling. It has been proposed that LETM1 exchanges mitochondrial  $\text{Ca}^{2+}$  for  $\text{H}^+$  when cytosolic  $\text{Ca}^{2+}$  levels are high and MCU mediates its import, whereas it acts as an alternative  $\text{Ca}^{2+}$  influx when cytosolic  $\text{Ca}^{2+}$  is low (Jiang et al., 2009). However, the role of LETM1 as  $\text{Ca}^{2+}/\text{H}^+$  antiporter remains matter of debate (Austin et al., 2017). Irrespective of these unresolved issues, it would be interesting to investigate whether LETM1 levels affect basal mitochondrial  $\text{Ca}^{2+}$  in cancer cells, as the remodeling of  $\text{Ca}^{2+}$  spikes in the mitochondrial matrix of malignant cells may constitute a pivotal factor in the regulation of tumor progression by mitochondrial  $\text{Ca}^{2+}$ .

Taken together, these observations delineate multiple mechanisms whereby alterations in mitochondrial  $\text{Ca}^{2+}$  signaling influence malignant transformation, tumor progression and response to therapy in the context of metabolic rewiring, ROS generation and resistance to cell death (**Figure 4**). In this context, agents targeting deregulated MCU activity (either directly or via MICU1 and MCUR1) may constitute promising candidates for the development of new anticancer drugs, especially for tumors that exhibit elevated oxidative phosphorylation.

## Other intraorganellar Ca<sup>2+</sup> defects in cancer cells

Ca<sup>2+</sup> concentrations in the lysosomal lumen are similar to reticular Ca<sup>2+</sup> levels (Christensen et al., 2002; Lloyd-Evans et al., 2008). Thus, despite their limited volume, lysosomes can release considerable amounts of Ca<sup>2+</sup>, mostly via the ROS- and PI(3,5)P<sub>2</sub>-sensitive channel TRPML1 (Fine et al., 2018). Lysosomal functions are critical for cancer cells undergoing autophagy as a consequence of nutrient deprivation or exposure to therapeutic agents (Galluzzi et al., 2017). Moreover, lysosomes located to the cell periphery support metastasis by releasing metalloproteases that digest the extracellular matrix (Naegeli et al., 2017). In line with this notion, transcription factors from the microphthalmia family, including melanocyte inducing transcription factor (MITF), transcription factor EB (TFEB), transcription factor EC (TFEC) and transcription factor binding to IGHM enhancer 3 (TFE3), are upregulated in a variety of tumors, where they support lysosomal biogenesis, autophagy and metabolism (Slade and Pulinilkunnil, 2017). Importantly, the activity of these transcription factors is largely regulated by lysosomal Ca<sup>2+</sup> efflux via TRPML1. This results in the Ca<sup>2+</sup>-dependent activation of calcineurin, an oligomeric enzyme with phosphatase activity (Park et al., 2019), and consequent dephosphorylation-dependent nuclear relocalization of the transcription factors (Medina et al., 2015).

This is particularly relevant for HRAS<sup>G12V</sup>-driven tumors, which are characterized by high levels of MITF and TFEB (Urbanelli et al., 2014). Both MITF and TFEB transactivate *TRPML1* and VAC14 component of PIKFYVE complex (*VAC14*) as they repress myotubularin 1 (*MTM1*), hence establishing a circuitry whereby both TRPML1 and its major activator (PI(3,5)P<sub>2</sub>, which is synthesized by VAC14 and degraded by MTM1) are abundant (Jung et al., 2019). Thus, in HRAS<sup>G12V</sup>-driven tumors exhibit constitutive release of lysosomal Ca<sup>2+</sup> that feed into a positive loop to further sustain MITF and TFEB activity (Jung et al., 2019). Moreover, high Ca<sup>2+</sup> efflux from lysosomes favors cancer growth by the mitogen-associated

protein kinase (MAPK) pathway as by supporting HRAS<sup>G12V</sup> activation at the PM via the formation of nanoclusters (Jung et al., 2019). Of note, lysosomal Ca<sup>2+</sup> release is also sensed by CALM1, resulting in the activation of mechanistic target of rapamycin complex 1 (MTORC1) at the lysosomal surface and the MTORC1-dependent transduction of a mitogenic signal (Li et al., 2016; Sun et al., 2018), at least in triple-negative breast cancer (Xu et al., 2019). Curiously, TRPML1 inhibits, rather than activates, MTORC1 and MAPK signaling in melanoma, but still supports tumor progression (Kasitinon et al., 2019). The precise mechanisms underlying the ability of TRPML1 to drive melanoma progression in the context of MTORC1 and MAPK inhibition remain obscure, but may be linked to autophagy activation (given the major inhibitory role of MTORC1 on autophagy) (Rybstein et al., 2018).

Since also endolysosomal Ca<sup>2+</sup> exit through TPCN2 promotes proliferation and metastasis in breast cancer cells (Favia et al., 2014; Nguyen et al., 2017), lysosomal Ca<sup>2+</sup> release may constitute a general oncogenic factor, pointing to VAC14, TRPML1 and TPCN2 as potential candidates for the development of novel therapeutic agents. Besides the ability of lysosomal Ca<sup>2+</sup> to initiate transcriptional programs that support proliferation and adaptation to adverse microenvironmental conditions, such a key role may also reflect the ability lysosomes to evoke localized Ca<sup>2+</sup> puffs that promote migration (Wei et al., 2009). Moreover, under specific conditions lysosomes relocate in the proximity of the ER and PM, hence influencing ER Ca<sup>2+</sup> release (Atakpa et al., 2018) and SOCE (Sbano et al., 2017). Finally, lysosomes positioned at strategic intracellular sites could act as alternative Ca<sup>2+</sup>-buffering systems, limiting the continuous Ca<sup>2+</sup> transfer from the ER to mitochondria as or excessive Ca<sup>2+</sup> influx from the extracellular space, *de facto* mediating robust cytoprotective effects. These latter possibility remains to be formally investigated.

Ca<sup>2+</sup> homeostasis at the GA has also been linked to malignant transformation and tumor progression. Aging *Atp2c1*<sup>+/-</sup> mice (which are heterozygous for an ubiquitous SPCA) display

an increased incidence of squamous cell carcinomas (Okunade et al., 2007). However, it is not clear whether this phenotype can be ascribed to defects in  $\text{Ca}^{2+}$  fluxes, since ATPase secretory pathway  $\text{Ca}^{2+}$  transporting 1 (ATP2C1, best known as SPCA1) inhibition in triple-negative breast cancer cells does not impose profound changes to cytosolic  $\text{Ca}^{2+}$  signaling (Grice et al., 2010). Upregulation of ATPase secretory pathway  $\text{Ca}^{2+}$  transporting 2 (ATP2C2, best known as SPCA2) occurs physiologically during lactation (Faddy et al., 2008), and has been documented in numerous cases of breast cancer (Feng et al., 2010). In this context, SPCA2 mediates constitutive  $\text{Ca}^{2+}$  influx by enhancing ORAI1 activity in a store-independent manner, ultimately favoring the nuclear translocation of NFATC1 in support of proliferation and disease progression (Feng et al., 2010). Thus, the activity of SPCA2 in breast cancer resembles that ORAI3 in prostate carcinoma, also constituting a potential target for the development of novel anticancer agents. Although the actual contribution of  $\text{Ca}^{2+}$  fluxes within the GA to malignant transformation and tumor progression has never been investigated in detail, circumstantial evidence points to a potential link. Notably, TFE3 activation, which characterizes multiple tumors including pancreatic ductal adenocarcinoma (Perera et al., 2015), also ensues GA stress caused by alterations in GA  $\text{Ca}^{2+}$  levels upon SPCA1 overexpression (Smaardijk et al., 2018) or downregulation (Lissandron et al., 2010). It would be interesting to investigate whether the propensity of aging *Atp2c1*<sup>+/-</sup> mice to develop squamous cell carcinomas can be abrogated by blocking or deleting TFE3.

Irrespective of these and other open issues, lysosomes and the GA stand out as important but underestimated regulators of  $\text{Ca}^{2+}$  homeostasis that impact multiple steps of the carcinogenic process (**Figure 5**). We surmise that additional investigation may reveal potential targets other than SPCA2 for the development of novel anticancer agents that modulate  $\text{Ca}^{2+}$  fluxes at lysosomes and the GA.

## Therapeutic perspectives and concluding remarks

Although  $\text{Ca}^{2+}$  deregulation has long been viewed as a bystander of malignant transformation, tumor progression and resistance to therapy, accumulating preclinical and clinical evidence support a central role for alterations in  $\text{Ca}^{2+}$  homeostasis in cancer. Thus,  $\text{Ca}^{2+}$  signaling has begun to attract attention as a potential target for the development of novel anticancer therapies.

In this context, promising  $\text{Ca}^{2+}$ -based anticancer therapeutics include agents that block components of the molecular machinery for  $\text{Ca}^{2+}$  homeostasis highly overexpressed in malignant *versus* non-malignant tissues, as well as molecules that inhibit  $\text{Ca}^{2+}$  transporters conferring low susceptibility to cell death and concomitantly sustaining cancer cell proliferation. In line with this notion, the TRPA1 inhibitor AM-0902, alone or in combination with chemotherapeutics (Takahashi et al., 2018), as well as the TRPV6-antagonistic peptides SOR-C13 and SOR-C27 (Bowen et al., 2013; Xue et al., 2018), mediate robust antineoplastic effects in mice, in the absence of significant toxicity. Notably, SOR-C13 is currently under clinical testing in patients with advanced refractory solid tumors (NCT03784677). An orally available blocker of TRPC6 (*i.e.*, BI 749327) also mediates beneficial effects *in vivo*, in models of cardiac and renal disease (Lin et al., 2019), but has not yet been investigated for its anticancer properties. That said, it will be crucial to determine whether these agents impair anticancer immunosurveillance (Galluzzi et al., 2018a; Rao et al., 2019), in thus far resembling SOCE and TRPM2 inhibitors (Gershkovitz et al., 2018; Weidinger et al., 2013). Finally, systemic TRPML1 inhibition may not be achievable as loss-of-function mutations in *MCOLN1* cause a lysosomal storage disease characterized by mental and motor retardation (Frei et al., 1998).

As an alternative, pharmacological activation  $\text{Ca}^{2+}$  channels overexpressed by malignant cell may be harnessed to evoke cytosolic  $\text{Ca}^{2+}$  overload and consequent MPT-driven cell death. Consistent with this notion, the TRPV4 activator GSK1016790A inhibits the growth of

TRPV4-positive human breast carcinomas established in immunodeficient mice (Peters et al., 2017). However, this approach may also favor the proliferation of cancer cell clones with limited sensitivity to cell death induction, *de facto* selecting and favoring the progression of chemoresistant disease. At least theoretically, concentrating  $\text{Ca}^{2+}$  overload in a restricted area of the cell may result in superior cytotoxicity, as demonstrated by the potent effect of PSMA-activatable thapsigargin (G-202 or mipsagargin) (Denmeade et al., 2012). However, despite encouraging results from early phase clinical trials enrolling patients with advanced solid tumors (Mahalingam et al., 2019; Mahalingam et al., 2016), the clinical development of G-202 for oncological indications appears to be at an impasse (source [www.clinicaltrials.gov](http://www.clinicaltrials.gov)).

$\text{IP}_3\text{R}$ s have also attracted attention as potential target for the development of anticancer agents. On the one hand,  $\text{IP}_3\text{R}$  inhibitors have been evaluated for their ability to limit ER-to-mitochondria  $\text{Ca}^{2+}$  transfer, hence blocking the proliferation of cancer cells relying on oxidative phosphorylation for ATP synthesis (Cardenas et al., 2016). On the other hand, molecules that modulate  $\text{IP}_3\text{R}$  activity, including small peptides that release  $\text{IP}_3\text{R}$  from BCL2-mediated inhibition (Akl et al., 2013; Bittremieux et al., 2019; Zhong et al., 2011) as well as chemical inhibitors of  $\text{IP}_3\text{R}$  degradation (Kuchay et al., 2017), have been investigated for the capacity to support  $\text{Ca}^{2+}$  overload culminating with cell death or sensitization to conventional chemotherapeutics. However, the toxic effects of these molecules remain largely unexplored.

Thus, to translate  $\text{Ca}^{2+}$ -based anticancer agents from the bench to the bedside, it will be important not only to identify molecules that selectively target  $\text{Ca}^{2+}$  homeostasis in malignant cells, but also to consider the metabolic heterogeneity of the latter and the mechanisms through which such a heterogeneity is connected to cell death regulation. Moreover, it will be critical to link altered  $\text{Ca}^{2+}$  fluxes in cancer cells to the ability of the latter to evade immunosurveillance, which is now recognized as a key hallmark of oncogenesis (Galluzzi et al., 2018a; Hanahan and Weinberg, 2011). The ER-resident  $\text{Ca}^{2+}$ -buffering chaperone

calreticulin (CALR) is expected to play a major role in this context, not only because CALR is critical for the proper loading of antigenic epitopes on the surface of MHC Class I molecules (Raghavan et al., 2013), but also since CALR is intimately involved in the ability of stressed and dying cancer cells to deliver stimulatory, adjuvant-like signals to immune cells (Galluzzi et al., 2020; Rodriguez-Ruiz et al., 2020; Salvagno and Cubillos-Ruiz, 2019). However, little is known on the effect of deranged  $\text{Ca}^{2+}$  homeostasis on the immunostimulatory effects of CALR in cancer cells. In conclusion, alterations in  $\text{Ca}^{2+}$  fluxes influence malignant transformation, tumor progression and response to therapy by affecting an intricate network of cancer cell-intrinsic (*e.g.*, metabolism, redox homeostasis) and extrinsic (*e.g.*, antigen presentation, danger signaling) functions. Additional work is urgently awaited to disentangle the molecular and functional complexity of such network.

**Author contributions and acknowledgements.** SM and LG conceived the review and wrote the first version of the manuscript, with constructive input from CG and PP. SM prepared display items (with Biorender.com) under the supervision of LG. All authors approved the final version of the manuscript. SM is supported by the Italian Ministry of Health (GR-2016-02364602) and local funds from Marche Polytechnic University (Ancona, Italy). CG is supported by local funds from the University of Ferrara, the Italian Association for Cancer Research (AIRC: IG19803), the Italian Ministry of Health (GR-2013-02356747), the European Research Council (ERC, 853057—InflaPML), and Progetti di Rilevante Interesse Nazionale (PRIN, 2017 7E9EPY). LG is supported by a Breakthrough Level 2 grant from the US Department of Defense (DoD), Breast Cancer Research Program (BRCP) (#BC180476P1), by a startup grant from the Dept. of Radiation Oncology at Weill Cornell Medicine (New York, US), by a Rapid Response Grant from the Functional Genomic Initiative (FGI) (New York, US), by industrial collaborations with Lytix (Oslo, Norway) and Phosplatin (New York, US), and by donations from Phosplatin (New York, US), the Luke Heller TECPR2 Foundation (Boston, US) and Sotio a.s. (Prague, Czech Republic). PP is grateful to Camilla degli Scrovegni for continuous support. PP is supported by the Italian Association for Cancer Research (AIRC, IG-23670), Telethon (GGP11139B), Progetti di Rilevante Interesse Nazionale (PRIN, 2017 E5L5P3) and local funds from the University of Ferrara.



## Legends to Figures

**Figure 1. Regulation of Ca<sup>2+</sup> in normal non-excitable cells.** In response to a variety of stimuli, normal non-excitable cells can activate cytosolic Ca<sup>2+</sup> signaling via a variety of mechanisms, including (but not limited to): (1) Ca<sup>2+</sup> release from the endoplasmic reticulum (ER) and the Golgi apparatus; (2) Ca<sup>2+</sup> release from mitochondria and lysosomes; as well as (3) Ca<sup>2+</sup> uptake from the extracellular microenvironment. This causes an increase in cytosolic Ca<sup>2+</sup> levels coupled to the activation of numerous cellular functions (**A**). Numerous systems contribute to the extinction of Ca<sup>2+</sup> signaling by reducing cytosolic Ca<sup>2+</sup> levels upon: (1) Ca<sup>2+</sup> import by the ER, Golgi apparatus and mitochondria; or (2) Ca<sup>2+</sup> extrusion to the extracellular space. Whether lysosomes accumulate Ca<sup>2+</sup> via specific transporters including a hitherto uncharacterized Ca<sup>2+</sup>/H<sup>+</sup> exchanger (CAX) or from the microenvironment upon endocytosis remains unclear (**B**). IP<sub>3</sub>R, 1,4,5-inositol trisphosphate receptor; MCU, mitochondrial calcium uniporter; NCLX (official name: SLC8B1), solute carrier family 8 member B1; PMCA, plasma membrane Ca<sup>2+</sup> ATPase; SERCA, sarcoendoplasmic reticular Ca<sup>2+</sup> ATPase; SPCA, secretory pathway Ca<sup>2+</sup> ATPase; STIM, stromal interaction molecule; TPCN, two pore segment channel; TRPML1 (official name: MCOLN1), mucolipin 1; TRP, transient receptor potential cation channel member; VDAC, voltage-dependent anion channel; VGCC, voltage-gated calcium channel.

**Figure 2. Cancer-associated alterations of Ca<sup>2+</sup> fluxes at the plasma membrane.** Malignant cells can harness multiple alterations of Ca<sup>2+</sup> fluxes at the plasma membrane in support of tumor progression or resistance to treatment. In particular, increased Ca<sup>2+</sup> entry upon overexpression of various transient receptor potential cation channel (TRP) family members, ORAI calcium release-activated calcium modulator 3 (ORAI3), or *ORAI1* mutations, as well as store-operated calcium entry (SOCE) inhibition downstream of ORAI downregulation, have been linked to

superior resistance to cell death and improved metastatic potential as a consequence of: (1) activation of antiapoptotic and mitogenic pathways; (2) establishment of antioxidant defenses; (3) autophagy initiation; (5) acquisition of increased motility; and (6) secretion of matrix metalloproteinases (MMPs). CALM1, calmodulin 1; CAMKK2, calcium/calmodulin dependent protein kinase kinase 2; MCL1, MCL1 apoptosis regulator, BCL2 family member; NFATC1, nuclear factor of activated T cells 1; NRF2 (official name: NFE2L2), nuclear factor, erythroid 2 like 2; PYK2 (official name: PTK2B), protein tyrosine kinase 2 beta.

**Figure 3. Cancer-associated defects of reticular  $\text{Ca}^{2+}$  homeostasis.** Acute sarcoendoplasmic reticular  $\text{Ca}^{2+}$  ATPase (SERCA) inhibition with thapsigargin is highly toxic for malignant (and non-malignant) cells as a consequence of 1,4,5-inositol trisphosphate receptor ( $\text{IP}_3\text{R}$ )-dependent cytosolic  $\text{Ca}^{2+}$  overload. Conversely, SERCA downregulation in cancer cells results in limited  $\text{Ca}^{2+}$  uptake by the endoplasmic reticulum (ER), hence limiting the pool available for release by  $\text{IP}_3\text{Rs}$  in response to ER-targeting chemotherapeutics, which *de facto* supports chemoresistance. A similar effect is mediated by AKT serine/threonine kinase 1 (AKT1) and antiapoptotic Bcl-2 family members, although the precise mechanisms whereby the latter deplete reticular  $\text{Ca}^{2+}$  remain to be elucidated. Conversely, mild upregulation of SERCAs expand the pool of  $\text{Ca}^{2+}$  that is available for release by  $\text{IP}_3\text{Rs}$ , resulting in increased  $\text{Ca}^{2+}$  release in baseline conditions. This results in improved mitochondrial functions as well as activation of NOTCH and WNT signaling in the absence of over cytotoxicity, ultimately promoting cancer cell proliferation and invasiveness. Similar oncogenic effects have been attributed to  $\text{IP}_3\text{R}$  upregulation, as well as to the ability of anti-apoptotic Bcl-2 family member to modulate  $\text{IP}_3\text{R}$  opening or promote ER  $\text{Ca}^{2+}$  leak. Representative  $\text{Ca}^{2+}$  fluctuations in the ER or cytoplasm of cells experiencing the depicted processes (*e.g.*, thapsigargin administration, SERCA-dependent  $\text{Ca}^{2+}$  uptake by the ER, etc..) in wild-type settings (black curves) or in the presence

of cancer-associated alterations (red curves) are represented. BCL2, BCL2 apoptosis regulator; BCL-X<sub>L</sub> (official name, BCL2L1), BCL2 like 1; PML, promyelocytic leukemia.

**Figure 4. Alterations of mitochondrial Ca<sup>2+</sup> signaling in cancer cells.** At high mitochondrial calcium uniporter (MCU) to mitochondrial calcium uptake 1 (MICU1) ratios, cancer cells accumulate higher Ca<sup>2+</sup> levels in mitochondria at baseline, resulting in increased proliferation as a consequence of accrued ATP and reactive oxygen species (ROS) production. ROS also favors metastatic dissemination by promoting hypoxia inducible factor 1 subunit alpha (HIF1A)-dependent transcription programs and matrix metalloproteinase 2 (MMP2) activation. Similar effects can result from MICU1 inhibition by AKT serine/threonine kinase 1 (AKT1). Conversely, low MCU/MICU1 ratios limit mitochondrial Ca<sup>2+</sup> entry and hence protect cancer cells from death induced by chemotherapeutics. Finally, upregulation of mitochondrial calcium uptake regulator 1 (MCUR1) results in increased Ca<sup>2+</sup> uptake by mitochondria along with activation of a ROS-dependent antioxidant response orchestrated by nuclear factor, erythroid 2 like 2 (NFE2L2, best known as NRF2) and involving tumor protein p53 (TP53) degradation. Whether MCUR1 is a bona fide component of the MCU complex remains unclear.

**Figure 5. Defects of Ca<sup>2+</sup> fluxes in the lysosomes and Golgi apparatus of malignant cells.** Increased Ca<sup>2+</sup> release from lysosomes as a consequence of mucolipin 1 (MCOLN1, also known as TRPML1) or two pore segment channel 2 (TPCN2) upregulation can favor cancer cell proliferation via mechanistic target of rapamycin complex 1 (MTORC1), AKT serine/threonine kinase 1 (AKT1) or mutant HRas proto-oncogene, GTPase (HRAS), as well as the activation of lysosomal biogenesis and autophagy via transcription factor EB (TFEB). Similar effects can occur downstream of Golgi apparatus (GA) stress caused by alterations in the levels of ATPase secretory pathway Ca<sup>2+</sup> transporting 1 (ATP2C1, best known as SPCA1) or SPCA2. In this latter setting, cytoprotective and mitogenic effects have been attributed to

the activation of transcription factor binding to IGHM enhancer 3 (TFE3) and nuclear factor of activated T cells 1 (NFATC1)-dependent transcriptional programs, respectively. Notably, NFATC1 driven by GA stress involves a compensatory increase in  $\text{Ca}^{2+}$  uptake via ORAI calcium release-activated calcium modulator 1 (ORAI1). CALM1, calmodulin 1; CALN (official name: PPP3CA), protein phosphatase 3 catalytic subunit alpha.

## **Box 1. Mitochondria-associated ER membranes**

The smooth endoplasmic reticulum (ER) forms structural and functional connections with virtually all organelles, notably mitochondria. ER-mitochondria contact sites are closely opposed and tethered to each other, but membranes do not fuse as they maintain a typical distance of 20-50 nm (Wu et al., 2018). These so-called mitochondria-associated ER membranes (MAMs) have distinct biochemical properties and can be isolated by subcellular fractionation, which has been harnessed to identify the preferential localization to MAMs of multiple enzymes and regulatory proteins (Wieckowski et al., 2009). The proteomic profile of MAMs suggests that MAMs participate in numerous cellular functions including lipid transfer, inflammatory responses, autophagy, the control of redox homeostasis, and  $\text{Ca}^{2+}$  signaling. Thus, MAMs act as molecular platforms that decode a plethora of inputs for orchestrating various cellular responses (Galluzzi et al., 2012). It is therefore not surprising that defects in MAM integrity or composition have been linked to various pathological conditions, including cancer. In many cases, MAM alterations result in a drastic remodeling of ER-mitochondria  $\text{Ca}^{2+}$  transfer that support malignant transformation or tumor progression. This occurs not only because several oncogenic and oncosuppressive factors reside at MAMs, where they control the expression or function of different  $\text{Ca}^{2+}$  transporters (see main text), but also as a consequence of MAM breakdown. Notably, the correct architecture of MAMs is ensured by structural proteins including PDZ domain containing 8 (PDZD8), VAMP associated protein B and C (VAPB) and regulator of microtubule dynamics 3 (RMDN3, also known as PTPIP51). The preservation of a proper spacing between ER and mitochondrial membranes at MAMs is essential to regulate  $\text{Ca}^{2+}$  fluxes, metabolism and sensitivity to cell death, thus constituting a key factor for multiple cancer-related processes (Morciano et al., 2018).

## References

Akl, H., Monaco, G., La Rovere, R., Welkenhuyzen, K., Kiviluoto, S., Vervliet, T., Molgo, J., Distelhorst, C. W., Missiaen, L., Mikoshiba, K., *et al.* (2013). IP3R2 levels dictate the apoptotic sensitivity of diffuse large B-cell lymphoma cells to an IP3R-derived peptide targeting the BH4 domain of Bcl-2. *Cell Death Dis* 4, e632.

Antony, A. N., Paillard, M., Moffat, C., Juskeviciute, E., Correnti, J., Bolon, B., Rubin, E., Csordas, G., Seifert, E. L., Hoek, J. B., and Hajnoczky, G. (2016). MICU1 regulation of mitochondrial Ca(2+) uptake dictates survival and tissue regeneration. *Nat Commun* 7, 10955.

Arbabian, A., Brouland, J. P., Gelebart, P., Kovacs, T., Bobe, R., Enouf, J., and Papp, B. (2011). Endoplasmic reticulum calcium pumps and cancer. *Biofactors* 37, 139-149.

Atakpa, P., Thillaiappan, N. B., Mataragka, S., Prole, D. L., and Taylor, C. W. (2018). IP3 Receptors Preferentially Associate with ER-Lysosome Contact Sites and Selectively Deliver Ca(2+) to Lysosomes. *Cell Rep* 25, 3180-3193 e3187.

Austin, S., Tavakoli, M., Pfeiffer, C., Seifert, J., Mattarei, A., De Stefani, D., Zoratti, M., and Nowikovsky, K. (2017). LETM1-Mediated K(+) and Na(+) Homeostasis Regulates Mitochondrial Ca(2+) Efflux. *Front Physiol* 8, 839.

Azimi, I., Bong, A. H., Poo, G. X. H., Armitage, K., Lok, D., Roberts-Thomson, S. J., and Monteith, G. R. (2018). Pharmacological inhibition of store-operated calcium entry in MDA-MB-468 basal A breast cancer cells: consequences on calcium signalling, cell migration and proliferation. *Cell Mol Life Sci* 75, 4525-4537.

Azimi, I., Milevskiy, M. J. G., Kaemmerer, E., Turner, D., Yapa, K., Brown, M. A., Thompson, E. W., Roberts-Thomson, S. J., and Monteith, G. R. (2017). TRPC1 is a differential regulator of hypoxia-mediated events and Akt signalling in PTEN-deficient breast cancer cells. *J Cell Sci* 130, 2292-2305.

Bansal, A., and Simon, M. C. (2018). Glutathione metabolism in cancer progression and treatment resistance. *J Cell Biol* 217, 2291-2298.

Bao, L., Festa, F., Freet, C. S., Lee, J. P., Hirschler-Laszkiewicz, I. M., Chen, S. J., Keefer, K. A., Wang, H. G., Patterson, A. D., Cheung, J. Y., and Miller, B. A. (2019). The Human

Transient Receptor Potential Melastatin 2 Ion Channel Modulates ROS Through Nrf2. *Sci Rep* 9, 14132.

Bartok, A., Weaver, D., Golenar, T., Nichtova, Z., Katona, M., Bansaghi, S., Alzayady, K. J., Thomas, V. K., Ando, H., Mikoshiba, K., *et al.* (2019). IP3 receptor isoforms differently regulate ER-mitochondrial contacts and local calcium transfer. *Nat Commun* 10, 3726.

Bassik, M. C., Scorrano, L., Oakes, S. A., Pozzan, T., and Korsmeyer, S. J. (2004). Phosphorylation of BCL-2 regulates ER Ca<sup>2+</sup> homeostasis and apoptosis. *EMBO J* 23, 1207-1216.

Ben-Kasus Nissim, T., Zhang, X., Elazar, A., Roy, S., Stolwijk, J. A., Zhou, Y., Motiani, R. K., Gueguinou, M., Hempel, N., Hershfinkel, M., *et al.* (2017). Mitochondria control store-operated Ca(2+) entry through Na(+) and redox signals. *EMBO J* 36, 797-815.

Berridge, M. J., Bootman, M. D., and Roderick, H. L. (2003). Calcium signalling: dynamics, homeostasis and remodelling. *Nat Rev Mol Cell Biol* 4, 517-529.

Berridge, M. J., Lipp, P., and Bootman, M. D. (2000). The versatility and universality of calcium signalling. *Nat Rev Mol Cell Biol* 1, 11-21.

Betz, C., Stracka, D., Prescianotto-Baschong, C., Frieden, M., Demaurex, N., and Hall, M. N. (2013). Feature Article: mTOR complex 2-Akt signaling at mitochondria-associated endoplasmic reticulum membranes (MAM) regulates mitochondrial physiology. *Proc Natl Acad Sci U S A* 110, 12526-12534.

Bittremieux, M., La Rovere, R. M., Akl, H., Martines, C., Welkenhuyzen, K., Dubron, K., Baes, M., Janssens, A., Vandenberghe, P., Laurenti, L., *et al.* (2019). Constitutive IP3 signaling underlies the sensitivity of B-cell cancers to the Bcl-2/IP3 receptor disruptor BIRD-2. *Cell Death Differ* 26, 531-547.

Bononi, A., Giorgi, C., Patergnani, S., Larson, D., Verbruggen, K., Tanji, M., Pellegrini, L., Signorato, V., Olivetto, F., Pastorino, S., *et al.* (2017). BAP1 regulates IP3R3-mediated Ca(2+) flux to mitochondria suppressing cell transformation. *Nature* 546, 549-553.

Bonora, M., Wieckowski, M. R., Sinclair, D. A., Kroemer, G., Pinton, P., and Galluzzi, L. (2019). Targeting mitochondria for cardiovascular disorders: therapeutic potential and obstacles. *Nat Rev Cardiol* 16, 33-55.

Booth, D. M., Enyedi, B., Geiszt, M., Varnai, P., and Hajnoczky, G. (2016). Redox Nanodomains Are Induced by and Control Calcium Signaling at the ER-Mitochondrial Interface. *Mol Cell* 63, 240-248.

Bootman, M. D., and Bultynck, G. (2020). Fundamentals of Cellular Calcium Signaling: A Primer. *Cold Spring Harb Perspect Biol* 12.

Bowen, C. V., DeBay, D., Ewart, H. S., Gallant, P., Gormley, S., Ilenchuk, T. T., Iqbal, U., Lutes, T., Martina, M., Mealing, G., *et al.* (2013). In vivo detection of human TRPV6-rich tumors with anti-cancer peptides derived from soricidin. *PLoS One* 8, e58866.

Brouland, J. P., Gelebart, P., Kovacs, T., Enouf, J., Grossmann, J., and Papp, B. (2005). The loss of sarco/endoplasmic reticulum calcium transport ATPase 3 expression is an early event during the multistep process of colon carcinogenesis. *Am J Pathol* 167, 233-242.

Canales, J., Morales, D., Blanco, C., Rivas, J., Diaz, N., Angelopoulos, I., and Cerda, O. (2019). A TR(i)P to Cell Migration: New Roles of TRP Channels in Mechanotransduction and Cancer. *Front Physiol* 10, 757.

Cardenas, C., Muller, M., McNeal, A., Lovy, A., Jana, F., Bustos, G., Urra, F., Smith, N., Molgo, J., Diehl, J. A., *et al.* (2016). Selective Vulnerability of Cancer Cells by Inhibition of Ca(2+) Transfer from Endoplasmic Reticulum to Mitochondria. *Cell Rep* 14, 2313-2324.

Catterall, W. A. (2011). Voltage-gated calcium channels. *Cold Spring Harb Perspect Biol* 3, a003947.

Chakraborty, P. K., Mustafi, S. B., Xiong, X., Dwivedi, S. K. D., Nesin, V., Saha, S., Zhang, M., Dhanasekaran, D., Jayaraman, M., Mannel, R., *et al.* (2017). MICU1 drives glycolysis and chemoresistance in ovarian cancer. *Nat Commun* 8, 14634.

Chami, M., Gozuacik, D., Lagorce, D., Brini, M., Falson, P., Peaucellier, G., Pinton, P., Lecoq, H., Gougeon, M. L., le Maire, M., *et al.* (2001). SERCA1 truncated proteins unable

to pump calcium reduce the endoplasmic reticulum calcium concentration and induce apoptosis. *J Cell Biol* 153, 1301-1314.

Chantome, A., Potier-Cartereau, M., Clarysse, L., Fromont, G., Marionneau-Lambot, S., Gueguinou, M., Pages, J. C., Collin, C., Oullier, T., Girault, A., *et al.* (2013). Pivotal role of the lipid Raft SK3-Orai1 complex in human cancer cell migration and bone metastases. *Cancer Res* 73, 4852-4861.

Chen, J., Sitsel, A., Benoy, V., Sepulveda, M. R., and Vangheluwe, P. (2020). Primary Active Ca(2+) Transport Systems in Health and Disease. *Cold Spring Harb Perspect Biol* 12.

Chen, Y. F., Chiu, W. T., Chen, Y. T., Lin, P. Y., Huang, H. J., Chou, C. Y., Chang, H. C., Tang, M. J., and Shen, M. R. (2011). Calcium store sensor stromal-interaction molecule 1-dependent signaling plays an important role in cervical cancer growth, migration, and angiogenesis. *Proc Natl Acad Sci U S A* 108, 15225-15230.

Chen, Y. T., Chen, Y. F., Chiu, W. T., Liu, K. Y., Liu, Y. L., Chang, J. Y., Chang, H. C., and Shen, M. R. (2013). Microtubule-associated histone deacetylase 6 supports the calcium store sensor STIM1 in mediating malignant cell behaviors. *Cancer Res* 73, 4500-4509.

Chong, S., Marchi, S., Petroni, G., Kroemer, G., Galluzzi, L., and Pervaiz, S. (2020). Non-canonical cell fate regulation by Bcl-2 proteins. *Trends Cell Biol*, in press.

Choudhry, H., and Harris, A. L. (2018). Advances in Hypoxia-Inducible Factor Biology. *Cell Metab* 27, 281-298.

Christensen, K. A., Myers, J. T., and Swanson, J. A. (2002). pH-dependent regulation of lysosomal calcium in macrophages. *J Cell Sci* 115, 599-607.

Conlon, G. A., and Murray, G. I. (2019). Recent advances in understanding the roles of matrix metalloproteinases in tumour invasion and metastasis. *J Pathol* 247, 629-640.

Csordas, G., Golenar, T., Seifert, E. L., Kamer, K. J., Sancak, Y., Perocchi, F., Moffat, C., Weaver, D., de la Fuente Perez, S., Bogorad, R., *et al.* (2013). MICU1 controls both the threshold and cooperative activation of the mitochondrial Ca(2+)(+) uniporter. *Cell Metab* 17, 976-987.

Curry, M. C., Peters, A. A., Kenny, P. A., Roberts-Thomson, S. J., and Monteith, G. R. (2013). Mitochondrial calcium uniporter silencing potentiates caspase-independent cell death in MDA-MB-231 breast cancer cells. *Biochem Biophys Res Commun* 434, 695-700.

De Stefani, D., Bononi, A., Romagnoli, A., Messina, A., De Pinto, V., Pinton, P., and Rizzuto, R. (2012). VDAC1 selectively transfers apoptotic Ca<sup>2+</sup> signals to mitochondria. *Cell Death Differ* 19, 267-273.

Denmeade, S. R., Mhaka, A. M., Rosen, D. M., Brennen, W. N., Dalrymple, S., Dach, I., Olesen, C., Gurel, B., Demarzo, A. M., Wilding, G., *et al.* (2012). Engineering a prostate-specific membrane antigen-activated tumor endothelial cell prodrug for cancer therapy. *Sci Transl Med* 4, 140ra186.

Denton, R. M. (2009). Regulation of mitochondrial dehydrogenases by calcium ions. *Biochim Biophys Acta* 1787, 1309-1316.

Derler, I., Jardin, I., and Romanin, C. (2016). Molecular mechanisms of STIM/Orai communication. *Am J Physiol Cell Physiol* 310, C643-662.

Dong, Z., Shanmughapriya, S., Tomar, D., Siddiqui, N., Lynch, S., Nemani, N., Breves, S. L., Zhang, X., Tripathi, A., Palaniappan, P., *et al.* (2017). Mitochondrial Ca(2+) Uniporter Is a Mitochondrial Luminal Redox Sensor that Augments MCU Channel Activity. *Mol Cell* 65, 1014-1028 e1017.

Dubois, C., Vanden Abeele, F., Lehen'kyi, V., Gkika, D., Guarmit, B., Lepage, G., Slomianny, C., Borowiec, A. S., Bidaux, G., Benahmed, M., *et al.* (2014). Remodeling of channel-forming ORAI proteins determines an oncogenic switch in prostate cancer. *Cancer Cell* 26, 19-32.

Eckenrode, E. F., Yang, J., Velmurugan, G. V., Foskett, J. K., and White, C. (2010). Apoptosis protection by Mcl-1 and Bcl-2 modulation of inositol 1,4,5-trisphosphate receptor-dependent Ca<sup>2+</sup> signaling. *J Biol Chem* 285, 13678-13684.

Faddy, H. M., Smart, C. E., Xu, R., Lee, G. Y., Kenny, P. A., Feng, M., Rao, R., Brown, M. A., Bissell, M. J., Roberts-Thomson, S. J., and Monteith, G. R. (2008). Localization of plasma membrane and secretory calcium pumps in the mammary gland. *Biochem Biophys Res Commun* 369, 977-981.

Fan, L., Li, A., Li, W., Cai, P., Yang, B., Zhang, M., Gu, Y., Shu, Y., Sun, Y., Shen, Y., *et al.* (2014). Novel role of Sarco/endoplasmic reticulum calcium ATPase 2 in development of colorectal cancer and its regulation by F36, a curcumin analog. *Biomed Pharmacother* 68, 1141-1148.

Favia, A., Desideri, M., Gambara, G., D'Alessio, A., Ruas, M., Esposito, B., Del Bufalo, D., Parrington, J., Ziparo, E., Palombi, F., *et al.* (2014). VEGF-induced neoangiogenesis is mediated by NAADP and two-pore channel-2-dependent Ca<sup>2+</sup> signaling. *Proc Natl Acad Sci U S A* 111, E4706-4715.

Feng, M., Grice, D. M., Faddy, H. M., Nguyen, N., Leitch, S., Wang, Y., Muend, S., Kenny, P. A., Sukumar, S., Roberts-Thomson, S. J., *et al.* (2010). Store-independent activation of Orai1 by SPCA2 in mammary tumors. *Cell* 143, 84-98.

Fine, M., Schmiede, P., and Li, X. (2018). Structural basis for PtdInsP<sub>2</sub>-mediated human TRPML1 regulation. *Nat Commun* 9, 4192.

Fixemer, T., Wissenbach, U., Flockerzi, V., and Bonkhoff, H. (2003). Expression of the Ca<sup>2+</sup>-selective cation channel TRPV6 in human prostate cancer: a novel prognostic marker for tumor progression. *Oncogene* 22, 7858-7861.

Flourakis, M., Lehen'kyi, V., Beck, B., Raphael, M., Vandenberghe, M., Abeele, F. V., Roudbaraki, M., Lepage, G., Mauroy, B., Romanin, C., *et al.* (2010). Orai1 contributes to the establishment of an apoptosis-resistant phenotype in prostate cancer cells. *Cell Death Dis* 1, e75.

Frei, K. P., Patronas, N. J., Crutchfield, K. E., Altarescu, G., and Schiffmann, R. (1998). Mucopolipidosis type IV: characteristic MRI findings. *Neurology* 51, 565-569.

Frischauf, I., Litvinukova, M., Schober, R., Zayats, V., Svobodova, B., Bonhenry, D., Lunz, V., Cappello, S., Tociu, L., Reha, D., *et al.* (2017). Transmembrane helix connectivity in Orai1 controls two gates for calcium-dependent transcription. *Sci Signal* 10.

Frishman, W. H. (2007). Calcium channel blockers: differences between subclasses. *Am J Cardiovasc Drugs* 7 Suppl 1, 17-23.

Galluzzi, L., Bravo-San Pedro, J. M., Levine, B., Green, D. R., and Kroemer, G. (2017). Pharmacological modulation of autophagy: therapeutic potential and persisting obstacles. *Nat Rev Drug Discov* 16, 487-511.

Galluzzi, L., Chan, T. A., Kroemer, G., Wolchok, J. D., and Lopez-Soto, A. (2018a). The hallmarks of successful anticancer immunotherapy. *Sci Transl Med* 10.

Galluzzi, L., and Green, D. R. (2019). Autophagy-Independent Functions of the Autophagy Machinery. *Cell* 177, 1682-1699.

Galluzzi, L., Kepp, O., and Kroemer, G. (2012). Mitochondria: master regulators of danger signalling. *Nat Rev Mol Cell Biol* 13, 780-788.

Galluzzi, L., Kepp, O., Vander Heiden, M. G., and Kroemer, G. (2013). Metabolic targets for cancer therapy. *Nat Rev Drug Discov* 12, 829-846.

Galluzzi, L., Vitale, I., Aaronson, S. A., Abrams, J. M., Adam, D., Agostinis, P., Alnemri, E. S., Altucci, L., Amelio, I., Andrews, D. W., *et al.* (2018b). Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. *Cell Death Differ* 25, 486-541.

Galluzzi, L., Vitale, I., Warren, S., Adjemian, S., Agostinis, P., Martinez, A. B., Chan, T. A., Coukos, G., Demaria, S., Deutsch, E., *et al.* (2020). Consensus guidelines for the definition, detection and interpretation of immunogenic cell death. *J Immunother Cancer* 8, e000337.

Galluzzi, L., Yamazaki, T., and Kroemer, G. (2018c). Linking cellular stress responses to systemic homeostasis. *Nat Rev Mol Cell Biol* 19, 731-745.

Gershkovitz, M., Caspi, Y., Fainsod-Levi, T., Katz, B., Michaeli, J., Khawaled, S., Lev, S., Polyansky, L., Shaul, M. E., Sionov, R. V., *et al.* (2018). TRPM2 Mediates Neutrophil Killing of Disseminated Tumor Cells. *Cancer Res* 78, 2680-2690.

Ghosh, J. C., Siegelin, M. D., Vaira, V., Favarsani, A., Tavecchio, M., Chae, Y. C., Lisanti, S., Rampini, P., Giroda, M., Caino, M. C., *et al.* (2015). Adaptive mitochondrial reprogramming and resistance to PI3K therapy. *J Natl Cancer Inst* 107.

Giorgi, C., Bonora, M., Sorrentino, G., Missiroli, S., Poletti, F., Suski, J. M., Galindo Ramirez, F., Rizzuto, R., Di Virgilio, F., Zito, E., *et al.* (2015). p53 at the endoplasmic reticulum regulates apoptosis in a Ca<sup>2+</sup>-dependent manner. *Proc Natl Acad Sci U S A* *112*, 1779-1784.

Giorgi, C., Danese, A., Missiroli, S., Patergnani, S., and Pinton, P. (2018a). Calcium Dynamics as a Machine for Decoding Signals. *Trends Cell Biol* *28*, 258-273.

Giorgi, C., Ito, K., Lin, H. K., Santangelo, C., Wieckowski, M. R., Lebedzinska, M., Bononi, A., Bonora, M., Duszynski, J., Bernardi, R., *et al.* (2010). PML regulates apoptosis at endoplasmic reticulum by modulating calcium release. *Science* *330*, 1247-1251.

Giorgi, C., Marchi, S., and Pinton, P. (2018b). The machineries, regulation and cellular functions of mitochondrial calcium. *Nat Rev Mol Cell Biol* *19*, 713-730.

Gorrini, C., Harris, I. S., and Mak, T. W. (2013). Modulation of oxidative stress as an anticancer strategy. *Nat Rev Drug Discov* *12*, 931-947.

Grice, D. M., Vetter, I., Faddy, H. M., Kenny, P. A., Roberts-Thomson, S. J., and Monteith, G. R. (2010). Golgi calcium pump secretory pathway calcium ATPase 1 (SPCA1) is a key regulator of insulin-like growth factor receptor (IGF1R) processing in the basal-like breast cancer cell line MDA-MB-231. *J Biol Chem* *285*, 37458-37466.

Gualdani, R., de Clippele, M., Ratbi, I., Gailly, P., and Tajeddine, N. (2019). Store-Operated Calcium Entry Contributes to Cisplatin-Induced Cell Death in Non-Small Cell Lung Carcinoma. *Cancers (Basel)* *11*.

Guerra, M. T., Florentino, R. M., Franca, A., Lima Filho, A. C., Dos Santos, M. L., Fonseca, R. C., Lemos, F. O., Fonseca, M. C., Kruglov, E., Mennone, A., *et al.* (2019). Expression of the type 3 InsP3 receptor is a final common event in the development of hepatocellular carcinoma. *Gut* *68*, 1676-1687.

Guilbert, A., Dhennin-Duthille, I., Hiani, Y. E., Haren, N., Khorsi, H., Sevestre, H., Ahidouch, A., and Ouadid-Ahidouch, H. (2008). Expression of TRPC6 channels in human epithelial breast cancer cells. *BMC Cancer* *8*, 125.

Hall, D. P., Cost, N. G., Hegde, S., Kellner, E., Mikhaylova, O., Stratton, Y., Ehmer, B., Abplanalp, W. A., Pandey, R., Biesiada, J., *et al.* (2014). TRPM3 and miR-204 establish a

regulatory circuit that controls oncogenic autophagy in clear cell renal cell carcinoma. *Cancer Cell* 26, 738-753.

Hanahan, D., and Weinberg, R. A. (2011). Hallmarks of cancer: the next generation. *Cell* 144, 646-674.

Hasan, R., and Zhang, X. (2018). Ca<sup>2+</sup> Regulation of TRP Ion Channels. *Int J Mol Sci* 19.

Hasna, J., Hague, F., Rodat-Despoix, L., Geerts, D., Leroy, C., Tulasne, D., Ouadid-Ahidouch, H., and Kischel, P. (2018). Orai3 calcium channel and resistance to chemotherapy in breast cancer cells: the p53 connection. *Cell Death Differ* 25, 693-707.

Hawkins, B. J., Irrinki, K. M., Mallilankaraman, K., Lien, Y. C., Wang, Y., Bhanumathy, C. D., Subbiah, R., Ritchie, M. F., Soboloff, J., Baba, Y., *et al.* (2010). S-glutathionylation activates STIM1 and alters mitochondrial homeostasis. *J Cell Biol* 190, 391-405.

Hong, Z., Chen, K. H., DasGupta, A., Potus, F., Dunham-Snary, K., Bonnet, S., Tian, L., Fu, J., Breuils-Bonnet, S., Provencher, S., *et al.* (2017). MicroRNA-138 and MicroRNA-25 Downregulate Mitochondrial Calcium Uniporter, Causing the Pulmonary Arterial Hypertension Cancer Phenotype. *Am J Respir Crit Care Med* 195, 515-529.

Ibrahim, S., Dakik, H., Vandier, C., Chautard, R., Paintaud, G., Mazurier, F., Lecomte, T., Gueguinou, M., and Raoul, W. (2019). Expression Profiling of Calcium Channels and Calcium-Activated Potassium Channels in Colorectal Cancer. *Cancers (Basel)* 11.

Ivanova, H., Wagner, L. E., 2nd, Tanimura, A., Vandermarliere, E., Luyten, T., Welkenhuyzen, K., Alzayady, K. J., Wang, L., Hamada, K., Mikoshiba, K., *et al.* (2019). Bcl-2 and IP3 compete for the ligand-binding domain of IP3Rs modulating Ca<sup>2+</sup> signaling output. *Cell Mol Life Sci* 76, 3843-3859.

Jain, R., Watson, U., Vasudevan, L., and Saini, D. K. (2018). ERK Activation Pathways Downstream of GPCRs. *Int Rev Cell Mol Biol* 338, 79-109.

Jiang, D., Zhao, L., and Clapham, D. E. (2009). Genome-wide RNAi screen identifies Letm1 as a mitochondrial Ca<sup>2+</sup>/H<sup>+</sup> antiporter. *Science* 326, 144-147.

Jin, M., Wang, J., Ji, X., Cao, H., Zhu, J., Chen, Y., Yang, J., Zhao, Z., Ren, T., and Xing, J. (2019). MCUR1 facilitates epithelial-mesenchymal transition and metastasis via the

mitochondrial calcium dependent ROS/Nrf2/Notch pathway in hepatocellular carcinoma. *J Exp Clin Cancer Res* 38, 136.

Jung, J., Cho, K. J., Naji, A. K., Clemons, K. N., Wong, C. O., Villanueva, M., Gregory, S., Karagas, N. E., Tan, L., Liang, H., *et al.* (2019). HRAS-driven cancer cells are vulnerable to TRPML1 inhibition. *EMBO Rep* 20.

Kamer, K. J., and Mootha, V. K. (2015). The molecular era of the mitochondrial calcium uniporter. *Nat Rev Mol Cell Biol* 16, 545-553.

Kasitinon, S. Y., Eskiocak, U., Martin, M., Bezwada, D., Khivansara, V., Tasdogan, A., Zhao, Z., Mathews, T., Aurora, A. B., and Morrison, S. J. (2019). TRPML1 Promotes Protein Homeostasis in Melanoma Cells by Negatively Regulating MAPK and mTORC1 Signaling. *Cell Rep* 28, 2293-2305 e2299.

Koval, O. M., Nguyen, E. K., Santhana, V., Fidler, T. P., Sebag, S. C., Rasmussen, T. P., Mittauer, D. J., Strack, S., Goswami, P. C., Abel, E. D., and Grumbach, I. M. (2019). Loss of MCU prevents mitochondrial fusion in G1-S phase and blocks cell cycle progression and proliferation. *Sci Signal* 12.

Kuchay, S., Giorgi, C., Simoneschi, D., Pagan, J., Missiroli, S., Saraf, A., Florens, L., Washburn, M. P., Collazo-Lorduy, A., Castillo-Martin, M., *et al.* (2017). PTEN counteracts FBXL2 to promote IP3R3- and Ca(2+)-mediated apoptosis limiting tumour growth. *Nature* 546, 554-558.

Li, P., Gu, M., and Xu, H. (2019). Lysosomal Ion Channels as Decoders of Cellular Signals. *Trends Biochem Sci* 44, 110-124.

Li, R. J., Xu, J., Fu, C., Zhang, J., Zheng, Y. G., Jia, H., and Liu, J. O. (2016). Regulation of mTORC1 by lysosomal calcium and calmodulin. *Elife* 5.

Lin, B. L., Matera, D., Doerner, J. F., Zheng, N., Del Camino, D., Mishra, S., Bian, H., Zeveleva, S., Zhen, X., Blair, N. T., *et al.* (2019). In vivo selective inhibition of TRPC6 by antagonist BI 749327 ameliorates fibrosis and dysfunction in cardiac and renal disease. *Proc Natl Acad Sci U S A* 116, 10156-10161.

Lissandron, V., Podini, P., Pizzo, P., and Pozzan, T. (2010). Unique characteristics of Ca<sup>2+</sup> homeostasis of the trans-Golgi compartment. *Proc Natl Acad Sci U S A* *107*, 9198-9203.

Lloyd-Evans, E., Morgan, A. J., He, X., Smith, D. A., Elliot-Smith, E., Sillence, D. J., Churchill, G. C., Schuchman, E. H., Galione, A., and Platt, F. M. (2008). Niemann-Pick disease type C1 is a sphingosine storage disease that causes deregulation of lysosomal calcium. *Nat Med* *14*, 1247-1255.

Lundgren, T. K., Nakahata, K., Fritz, N., Rebellato, P., Zhang, S., and Uhlen, P. (2012). RET PLCgamma phosphotyrosine binding domain regulates Ca<sup>2+</sup> signaling and neocortical neuronal migration. *PLoS One* *7*, e31258.

Lytton, J., Westlin, M., and Hanley, M. R. (1991). Thapsigargin inhibits the sarcoplasmic or endoplasmic reticulum Ca-ATPase family of calcium pumps. *J Biol Chem* *266*, 17067-17071.

Mahalingam, D., Peguero, J., Cen, P., Arora, S. P., Sarantopoulos, J., Rowe, J., Allgood, V., Tubb, B., and Campos, L. (2019). A Phase II, Multicenter, Single-Arm Study of Mipsagargin (G-202) as a Second-Line Therapy Following Sorafenib for Adult Patients with Progressive Advanced Hepatocellular Carcinoma. *Cancers (Basel)* *11*.

Mahalingam, D., Wilding, G., Denmeade, S., Sarantopoulos, J., Cosgrove, D., Cetnar, J., Azad, N., Bruce, J., Kurman, M., Allgood, V. E., and Carducci, M. (2016). Mipsagargin, a novel thapsigargin-based PSMA-activated prodrug: results of a first-in-man phase I clinical trial in patients with refractory, advanced or metastatic solid tumours. *Br J Cancer* *114*, 986-994.

Malli, R., and Graier, W. F. (2017). The Role of Mitochondria in the Activation/Maintenance of SOCE: The Contribution of Mitochondrial Ca(2+) Uptake, Mitochondrial Motility, and Location to Store-Operated Ca(2+) Entry. *Adv Exp Med Biol* *993*, 297-319.

Mallilankaraman, K., Cardenas, C., Doonan, P. J., Chandramoorthy, H. C., Irrinki, K. M., Golenar, T., Csordas, G., Madireddi, P., Yang, J., Muller, M., *et al.* (2012a). MCUR1 is an essential component of mitochondrial Ca<sup>2+</sup> uptake that regulates cellular metabolism. *Nat Cell Biol* *14*, 1336-1343.

Mallilankaraman, K., Doonan, P., Cardenas, C., Chandramoorthy, H. C., Muller, M., Miller, R., Hoffman, N. E., Gandhirajan, R. K., Molgo, J., Birnbaum, M. J., *et al.* (2012b). MICU1 is

an essential gatekeeper for MCU-mediated mitochondrial Ca(2+) uptake that regulates cell survival. *Cell* 151, 630-644.

Mangla, A., Guerra, M. T., and Nathanson, M. H. (2020). Type 3 inositol 1,4,5-trisphosphate receptor: A calcium channel for all seasons. *Cell Calcium* 85, 102132.

Marchi, S., Corricelli, M., Branchini, A., Vitto, V. A. M., Missiroli, S., Morciano, G., Perrone, M., Ferrarese, M., Giorgi, C., Pinotti, M., *et al.* (2019a). Akt-mediated phosphorylation of MICU1 regulates mitochondrial Ca(2+) levels and tumor growth. *EMBO J* 38.

Marchi, S., Giorgi, C., Oparka, M., Duszynski, J., Wieckowski, M. R., and Pinton, P. (2014). Oncogenic and oncosuppressive signal transduction at mitochondria-associated endoplasmic reticulum membranes. *Mol Cell Oncol* 1, e956469.

Marchi, S., Lupini, L., Patergnani, S., Rimessi, A., Missiroli, S., Bonora, M., Bononi, A., Corra, F., Giorgi, C., De Marchi, E., *et al.* (2013). Downregulation of the mitochondrial calcium uniporter by cancer-related miR-25. *Curr Biol* 23, 58-63.

Marchi, S., Marinello, M., Bononi, A., Bonora, M., Giorgi, C., Rimessi, A., and Pinton, P. (2012). Selective modulation of subtype III IP(3)R by Akt regulates ER Ca(2+)(+) release and apoptosis. *Cell Death Dis* 3, e304.

Marchi, S., Vitto, V. A. M., Danese, A., Wieckowski, M. R., Giorgi, C., and Pinton, P. (2019b). Mitochondrial calcium uniporter complex modulation in cancerogenesis. *Cell Cycle* 18, 1068-1083.

Marchi, S., Vitto, V. A. M., Patergnani, S., and Pinton, P. (2019c). High mitochondrial Ca(2+) content increases cancer cell proliferation upon inhibition of mitochondrial permeability transition pore (mPTP). *Cell Cycle* 18, 914-916.

Mazure, N. M. (2017). VDAC in cancer. *Biochim Biophys Acta Bioenerg* 1858, 665-673.

Medina, D. L., Di Paola, S., Peluso, I., Armani, A., De Stefani, D., Venditti, R., Montefusco, S., Scotto-Rosato, A., Prezioso, C., Forrester, A., *et al.* (2015). Lysosomal calcium signalling regulates autophagy through calcineurin and TFEB. *Nat Cell Biol* 17, 288-299.

Melchionda, M., Pittman, J. K., Mayor, R., and Patel, S. (2016). Ca<sup>2+</sup>/H<sup>+</sup> exchange by acidic organelles regulates cell migration in vivo. *J Cell Biol* 212, 803-813.

Mendes, C. C., Gomes, D. A., Thompson, M., Souto, N. C., Goes, T. S., Goes, A. M., Rodrigues, M. A., Gomez, M. V., Nathanson, M. H., and Leite, M. F. (2005). The type III inositol 1,4,5-trisphosphate receptor preferentially transmits apoptotic Ca<sup>2+</sup> signals into mitochondria. *J Biol Chem* *280*, 40892-40900.

Monet, M., Lehen'kyi, V., Gackiere, F., Firlej, V., Vandenberghe, M., Roudbaraki, M., Gkika, D., Pourtier, A., Bidaux, G., Slomianny, C., *et al.* (2010). Role of cationic channel TRPV2 in promoting prostate cancer migration and progression to androgen resistance. *Cancer Res* *70*, 1225-1235.

Monteith, G. R., Prevarskaya, N., and Roberts-Thomson, S. J. (2017). The calcium-cancer signalling nexus. *Nat Rev Cancer* *17*, 367-380.

Moran, M. M., McAlexander, M. A., Biro, T., and Szallasi, A. (2011). Transient receptor potential channels as therapeutic targets. *Nat Rev Drug Discov* *10*, 601-620.

Morciano, G., Marchi, S., Morganti, C., Sbano, L., Bittremieux, M., Kerkhofs, M., Corricelli, M., Danese, A., Karkucinska-Wieckowska, A., Wieckowski, M. R., *et al.* (2018). Role of Mitochondria-Associated ER Membranes in Calcium Regulation in Cancer-Specific Settings. *Neoplasia* *20*, 510-523.

Motiani, R. K., Abdullaev, I. F., and Trebak, M. (2010). A novel native store-operated calcium channel encoded by Orai3: selective requirement of Orai3 versus Orai1 in estrogen receptor-positive versus estrogen receptor-negative breast cancer cells. *J Biol Chem* *285*, 19173-19183.

Motiani, R. K., Zhang, X., Harmon, K. E., Keller, R. S., Matrougui, K., Bennett, J. A., and Trebak, M. (2013). Orai3 is an estrogen receptor alpha-regulated Ca<sup>2+</sup>(+) channel that promotes tumorigenesis. *Faseb j* *27*, 63-75.

Naegeli, K. M., Hastie, E., Garde, A., Wang, Z., Keeley, D. P., Gordon, K. L., Pani, A. M., Kelley, L. C., Morrissey, M. A., Chi, Q., *et al.* (2017). Cell Invasion In Vivo via Rapid Exocytosis of a Transient Lysosome-Derived Membrane Domain. *Dev Cell* *43*, 403-417 e410.

Nguyen, O. N., Grimm, C., Schneider, L. S., Chao, Y. K., Atzberger, C., Bartel, K., Watermann, A., Ulrich, M., Mayr, D., Wahl-Schott, C., *et al.* (2017). Two-Pore Channel Function Is Crucial for the Migration of Invasive Cancer Cells. *Cancer Res* *77*, 1427-1438.

Okunade, G. W., Miller, M. L., Azhar, M., Andringa, A., Sanford, L. P., Doetschman, T., Prasad, V., and Shull, G. E. (2007). Loss of the Atp2c1 secretory pathway Ca(2+)-ATPase (SPCA1) in mice causes Golgi stress, apoptosis, and midgestational death in homozygous embryos and squamous cell tumors in adult heterozygotes. *J Biol Chem* 282, 26517-26527.

Palmer, A. E., Jin, C., Reed, J. C., and Tsien, R. Y. (2004). Bcl-2-mediated alterations in endoplasmic reticulum Ca<sup>2+</sup> analyzed with an improved genetically encoded fluorescent sensor. *Proc Natl Acad Sci U S A* 101, 17404-17409.

Palty, R., Silverman, W. F., Hershfinkel, M., Caporale, T., Sensi, S. L., Parnis, J., Nolte, C., Fishman, D., Shoshan-Barmatz, V., Herrmann, S., *et al.* (2010). NCLX is an essential component of mitochondrial Na<sup>+</sup>/Ca<sup>2+</sup> exchange. *Proc Natl Acad Sci U S A* 107, 436-441.

Park, H. S., Lee, S. C., Cardenas, M. E., and Heitman, J. (2019). Calcium-Calmodulin-Calcineurin Signaling: A Globally Conserved Virulence Cascade in Eukaryotic Microbial Pathogens. *Cell Host Microbe* 26, 453-462.

Paupe, V., Prudent, J., Dassa, E. P., Rendon, O. Z., and Shoubridge, E. A. (2015). CCDC90A (MCUR1) is a cytochrome c oxidase assembly factor and not a regulator of the mitochondrial calcium uniporter. *Cell Metab* 21, 109-116.

Perera, R. M., Stoykova, S., Nicolay, B. N., Ross, K. N., Fitamant, J., Boukhali, M., Lengrand, J., Deshpande, V., Selig, M. K., Ferrone, C. R., *et al.* (2015). Transcriptional control of autophagy-lysosome function drives pancreatic cancer metabolism. *Nature* 524, 361-365.

Pervaiz, S. (2018). Redox Dichotomy in Cell Fate Decision: Evasive Mechanism or Achilles Heel? *Antioxid Redox Signal* 29, 1191-1195.

Peters, A. A., Jamaludin, S. Y. N., Yapa, K., Chalmers, S., Wiegmans, A. P., Lim, H. F., Milevskiy, M. J. G., Azimi, I., Davis, F. M., Northwood, K. S., *et al.* (2017). Oncosis and apoptosis induction by activation of an overexpressed ion channel in breast cancer cells. *Oncogene* 36, 6490-6500.

Phan, N. N., Wang, C. Y., Chen, C. F., Sun, Z., Lai, M. D., and Lin, Y. C. (2017). Voltage-gated calcium channels: Novel targets for cancer therapy. *Oncol Lett* 14, 2059-2074.

Piao, L., Li, Y., Kim, S. J., Byun, H. S., Huang, S. M., Hwang, S. K., Yang, K. J., Park, K. A., Won, M., Hong, J., *et al.* (2009). Association of LETM1 and MRPL36 contributes to the regulation of mitochondrial ATP production and necrotic cell death. *Cancer Res* 69, 3397-3404.

Pierro, C., Cook, S. J., Foets, T. C., Bootman, M. D., and Roderick, H. L. (2014). Oncogenic K-Ras suppresses IP(3)-dependent Ca(2+)(+) release through remodelling of the isoform composition of IP(3)Rs and ER luminal Ca(2+)(+) levels in colorectal cancer cell lines. *J Cell Sci* 127, 1607-1619.

Pierro, C., Zhang, X., Kankeu, C., Trebak, M., Bootman, M. D., and Roderick, H. L. (2018). Oncogenic KRAS suppresses store-operated Ca(2+) entry and ICRAC through ERK pathway-dependent remodelling of STIM expression in colorectal cancer cell lines. *Cell Calcium* 72, 70-80.

Pinton, P., Ferrari, D., Magalhaes, P., Schulze-Osthoff, K., Di Virgilio, F., Pozzan, T., and Rizzuto, R. (2000). Reduced loading of intracellular Ca(2+) stores and downregulation of capacitative Ca(2+) influx in Bcl-2-overexpressing cells. *J Cell Biol* 148, 857-862.

Pinton, P., Ferrari, D., Rapizzi, E., Di Virgilio, F., Pozzan, T., and Rizzuto, R. (2001). The Ca<sup>2+</sup> concentration of the endoplasmic reticulum is a key determinant of ceramide-induced apoptosis: significance for the molecular mechanism of Bcl-2 action. *EMBO J* 20, 2690-2701.

Porporato, P. E., Filigheddu, N., Pedro, J. M. B., Kroemer, G., and Galluzzi, L. (2018). Mitochondrial metabolism and cancer. *Cell Res* 28, 265-280.

Potter, D. S., and Letai, A. (2016). To Prime, or Not to Prime: That Is the Question. *Cold Spring Harb Symp Quant Biol* 81, 131-140.

Prasad, V., Boivin, G. P., Miller, M. L., Liu, L. H., Erwin, C. R., Warner, B. W., and Shull, G. E. (2005). Haploinsufficiency of *Atp2a2*, encoding the sarco(endo)plasmic reticulum Ca<sup>2+</sup>-ATPase isoform 2 Ca<sup>2+</sup> pump, predisposes mice to squamous cell tumors via a novel mode of cancer susceptibility. *Cancer Res* 65, 8655-8661.

Prole, D. L., and Taylor, C. W. (2019). Structure and Function of IP<sub>3</sub> Receptors. *Cold Spring Harb Perspect Biol* 11.

Raghavan, M., Wijeyesakere, S. J., Peters, L. R., and Del Cid, N. (2013). Calreticulin in the immune system: ins and outs. *Trends Immunol* *34*, 13-21.

Rao, S., Gharib, K., and Han, A. (2019). Cancer Immunosurveillance by T Cells. *Int Rev Cell Mol Biol* *342*, 149-173.

Raturi, A., Gutierrez, T., Ortiz-Sandoval, C., Ruangkittisakul, A., Herrera-Cruz, M. S., Rockley, J. P., Gesson, K., Ourdev, D., Lou, P. H., Lucchinetti, E., *et al.* (2016). TMX1 determines cancer cell metabolism as a thiol-based modulator of ER-mitochondria Ca<sup>2+</sup> flux. *J Cell Biol* *214*, 433-444.

Ren, T., Wang, J., Zhang, H., Yuan, P., Zhu, J., Wu, Y., Huang, Q., Guo, X., Zhang, J., Ji, L., *et al.* (2018). MCUR1-Mediated Mitochondrial Calcium Signaling Facilitates Cell Survival of Hepatocellular Carcinoma via Reactive Oxygen Species-Dependent P53 Degradation. *Antioxid Redox Signal* *28*, 1120-1136.

Ren, T., Zhang, H., Wang, J., Zhu, J., Jin, M., Wu, Y., Guo, X., Ji, L., Huang, Q., Zhang, H., *et al.* (2017). MCU-dependent mitochondrial Ca<sup>(2+)</sup> inhibits NAD(+)/SIRT3/SOD2 pathway to promote ROS production and metastasis of HCC cells. *Oncogene* *36*, 5897-5909.

Roberts-Thomson, S. J., Chalmers, S. B., and Monteith, G. R. (2019). The Calcium-Signaling Toolkit in Cancer: Remodeling and Targeting. *Cold Spring Harb Perspect Biol* *11*.

Roderick, H. L., Berridge, M. J., and Bootman, M. D. (2003). Calcium-induced calcium release. *Curr Biol* *13*, R425.

Rodriguez-Ruiz, M. E., Vitale, I., Harrington, K. J., Melero, I., and Galluzzi, L. (2020). Immunological impact of cell death signaling driven by radiation on the tumor microenvironment. *Nat Immunol* *21*, 120-134.

Rong, Y. P., Bultynck, G., Aromolaran, A. S., Zhong, F., Parys, J. B., De Smedt, H., Mignery, G. A., Roderick, H. L., Bootman, M. D., and Distelhorst, C. W. (2009). The BH4 domain of Bcl-2 inhibits ER calcium release and apoptosis by binding the regulatory and coupling domain of the IP3 receptor. *Proc Natl Acad Sci U S A* *106*, 14397-14402.

Roti, G., Carlton, A., Ross, K. N., Markstein, M., Pajcini, K., Su, A. H., Perrimon, N., Pear, W. S., Kung, A. L., Blacklow, S. C., *et al.* (2013). Complementary genomic screens identify SERCA as a therapeutic target in NOTCH1 mutated cancer. *Cancer Cell* *23*, 390-405.

Rybarczyk, P., Vanlaeys, A., Brassart, B., Dhennin-Duthille, I., Chatelain, D., Sevestre, H., Ouadid-Ahidouch, H., and Gautier, M. (2017). The Transient Receptor Potential Melastatin 7 Channel Regulates Pancreatic Cancer Cell Invasion through the Hsp90alpha/uPA/MMP2 pathway. *Neoplasia* *19*, 288-300.

Rybstein, M. D., Bravo-San Pedro, J. M., Kroemer, G., and Galluzzi, L. (2018). The autophagic network and cancer. *Nat Cell Biol* *20*, 243-251.

Salvagno, C., and Cubillos-Ruiz, J. R. (2019). The impact of endoplasmic reticulum stress responses in dendritic cell immunobiology. *Int Rev Cell Mol Biol* *349*, 153-176.

Sbano, L., Bonora, M., Marchi, S., Baldassari, F., Medina, D. L., Ballabio, A., Giorgi, C., and Pinton, P. (2017). TFEB-mediated increase in peripheral lysosomes regulates store-operated calcium entry. *Sci Rep* *7*, 40797.

Schwaller, B. (2020). Cytosolic Ca(2+) Buffers Are Inherently Ca(2+) Signal Modulators. *Cold Spring Harb Perspect Biol* *12*.

Shapovalov, G., Lehen'kyi, V., Skryma, R., and Prevarskaya, N. (2011). TRP channels in cell survival and cell death in normal and transformed cells. *Cell Calcium* *50*, 295-302.

Shimizu, H., Schredelseker, J., Huang, J., Lu, K., Naghdi, S., Lu, F., Franklin, S., Fiji, H. D., Wang, K., Zhu, H., *et al.* (2015). Mitochondrial Ca(2+) uptake by the voltage-dependent anion channel 2 regulates cardiac rhythmicity. *Elife* *4*.

Shimizu, S., Narita, M., and Tsujimoto, Y. (1999). Bcl-2 family proteins regulate the release of apoptogenic cytochrome c by the mitochondrial channel VDAC. *Nature* *399*, 483-487.

Singh, R., Letai, A., and Sarosiek, K. (2019). Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins. *Nat Rev Mol Cell Biol* *20*, 175-193.

Slade, L., and Pulinilkunnil, T. (2017). The MiTF/TFE Family of Transcription Factors: Master Regulators of Organelle Signaling, Metabolism, and Stress Adaptation. *Mol Cancer Res* *15*, 1637-1643.

Smaardijk, S., Chen, J., Kerselaers, S., Voets, T., Eggermont, J., and Vangheluwe, P. (2018). Store-independent coupling between the Secretory Pathway  $\text{Ca}^{2+}$  transport ATPase SPCA1 and Orai1 in Golgi stress and Hailey-Hailey disease. *Biochim Biophys Acta Mol Cell Res* 1865, 855-862.

Stransky, N., Egloff, A. M., Tward, A. D., Kostic, A. D., Cibulskis, K., Sivachenko, A., Kryukov, G. V., Lawrence, M. S., Sougnez, C., McKenna, A., *et al.* (2011). The mutational landscape of head and neck squamous cell carcinoma. *Science* 333, 1157-1160.

Suisse, A., and Treisman, J. E. (2019). Reduced SERCA Function Preferentially Affects Wnt Signaling by Retaining E-Cadherin in the Endoplasmic Reticulum. *Cell Rep* 26, 322-329 e323.

Sun, C., Shui, B., Zhao, W., Liu, H., Li, W., Lee, J. C., Doran, R., Lee, F. K., Sun, T., Shen, Q. S., *et al.* (2019). Central role of IP3R2-mediated  $\text{Ca}^{2+}$  oscillation in self-renewal of liver cancer stem cells elucidated by high-signal ER sensor. *Cell Death Dis* 10, 396.

Sun, J., Lu, F., He, H., Shen, J., Messina, J., Mathew, R., Wang, D., Sarnaik, A. A., Chang, W. C., Kim, M., *et al.* (2014). STIM1- and Orai1-mediated  $\text{Ca}^{2+}$  oscillation orchestrates invadopodium formation and melanoma invasion. *J Cell Biol* 207, 535-548.

Sun, X., Yang, Y., Zhong, X. Z., Cao, Q., Zhu, X. H., Zhu, X., and Dong, X. P. (2018). A negative feedback regulation of MTORC1 activity by the lysosomal  $\text{Ca}^{2+}$  channel MCOLN1 (mucolipin 1) using a CALM (calmodulin)-dependent mechanism. *Autophagy* 14, 38-52.

Tajeddine, N., Galluzzi, L., Kepp, O., Hangen, E., Morselli, E., Senovilla, L., Araujo, N., Pinna, G., Larochette, N., Zamzami, N., *et al.* (2008). Hierarchical involvement of Bak, VDAC1 and Bax in cisplatin-induced cell death. *Oncogene* 27, 4221-4232.

Takahashi, N., Chen, H. Y., Harris, I. S., Stover, D. G., Selfors, L. M., Bronson, R. T., Deraedt, T., Cichowski, K., Welm, A. L., Mori, Y., *et al.* (2018). Cancer Cells Co-opt the Neuronal Redox-Sensing Channel TRPA1 to Promote Oxidative-Stress Tolerance. *Cancer Cell* 33, 985-1003 e1007.

Thompson, J. L., Mignen, O., and Shuttleworth, T. J. (2013). The ARC channel--an endogenous store-independent Orai channel. *Curr Top Membr* 71, 125-148.

Tosatto, A., Sommaggio, R., Kummerow, C., Bentham, R. B., Blacker, T. S., Berecz, T., Duchen, M. R., Rosato, A., Bogeski, I., Szabadkai, G., *et al.* (2016). The mitochondrial calcium uniporter regulates breast cancer progression via HIF-1alpha. *EMBO Mol Med* 8, 569-585.

Tsai, F. C., Seki, A., Yang, H. W., Hayer, A., Carrasco, S., Malmersjo, S., and Meyer, T. (2014). A polarized Ca<sup>2+</sup>, diacylglycerol and STIM1 signalling system regulates directed cell migration. *Nat Cell Biol* 16, 133-144.

Ueasilamongkol, P., Khamphaya, T., Guerra, M. T., Rodrigues, M. A., Gomes, D. A., Kong, Y., Wei, W., Jain, D., Trampert, D. C., Ananthanarayanan, M., *et al.* (2019). Type 3 Inositol 1,4,5-Trisphosphate Receptor Is Increased and Enhances Malignant Properties in Cholangiocarcinoma. *Hepatology*.

Urbanelli, L., Magini, A., Ercolani, L., Sagini, K., Polchi, A., Tancini, B., Brozzi, A., Armeni, T., Principato, G., and Emiliani, C. (2014). Oncogenic H-Ras up-regulates acid beta-hexosaminidase by a mechanism dependent on the autophagy regulator TFEB. *PLoS One* 9, e89485.

Vaseva, A. V., Marchenko, N. D., Ji, K., Tsirka, S. E., Holzmann, S., and Moll, U. M. (2012). p53 opens the mitochondrial permeability transition pore to trigger necrosis. *Cell* 149, 1536-1548.

Venkatachalam, K., and Montell, C. (2007). TRP channels. *Annu Rev Biochem* 76, 387-417.

Vitale, I., Manic, G., Coussens, L. M., Kroemer, G., and Galluzzi, L. (2019). Macrophages and Metabolism in the Tumor Microenvironment. *Cell Metab* 30, 36-50.

Vultur, A., Gibhardt, C. S., Stanis, H., and Bogeski, I. (2018). The role of the mitochondrial calcium uniporter (MCU) complex in cancer. *Pflugers Arch* 470, 1149-1163.

Wang, Y. Y., Chang, R. B., Waters, H. N., McKemy, D. D., and Liman, E. R. (2008). The nociceptor ion channel TRPA1 is potentiated and inactivated by permeating calcium ions. *J Biol Chem* 283, 32691-32703.

Wei, C., Wang, X., Chen, M., Ouyang, K., Song, L. S., and Cheng, H. (2009). Calcium flickers steer cell migration. *Nature* 457, 901-905.

Weidinger, C., Shaw, P. J., and Feske, S. (2013). STIM1 and STIM2-mediated Ca(2+) influx regulates antitumour immunity by CD8(+) T cells. *EMBO Mol Med* 5, 1311-1321.

Weiss, N., and Zamponi, G. W. (2019). T-type calcium channels: From molecule to therapeutic opportunities. *Int J Biochem Cell Biol* 108, 34-39.

White, C., Li, C., Yang, J., Petrenko, N. B., Madesh, M., Thompson, C. B., and Foskett, J. K. (2005). The endoplasmic reticulum gateway to apoptosis by Bcl-X(L) modulation of the InsP3R. *Nat Cell Biol* 7, 1021-1028.

Wieckowski, M. R., Giorgi, C., Lebiedzinska, M., Duszynski, J., and Pinton, P. (2009). Isolation of mitochondria-associated membranes and mitochondria from animal tissues and cells. *Nat Protoc* 4, 1582-1590.

Wu, H., Carvalho, P., and Voeltz, G. K. (2018). Here, there, and everywhere: The importance of ER membrane contact sites. *Science* 361.

Xu, M., Almasi, S., Yang, Y., Yan, C., Sterea, A. M., Rizvi Syeda, A. K., Shen, B., Richard Derek, C., Huang, P., Gujar, S., *et al.* (2019). The lysosomal TRPML1 channel regulates triple negative breast cancer development by promoting mTORC1 and purinergic signaling pathways. *Cell Calcium* 79, 80-88.

Xue, H., Wang, Y., MacCormack, T. J., Lutes, T., Rice, C., Davey, M., Dugourd, D., Ilenchuk, T. T., and Stewart, J. M. (2018). Inhibition of Transient Receptor Potential Vanilloid 6 channel, elevated in human ovarian cancers, reduces tumour growth in a xenograft model. *J Cancer* 9, 3196-3207.

Yang, J., Zhao, Z., Gu, M., Feng, X., and Xu, H. (2019). Release and uptake mechanisms of vesicular Ca(2+) stores. *Protein Cell* 10, 8-19.



Yang, S., Zhang, J. J., and Huang, X. Y. (2009). Orai1 and STIM1 are critical for breast tumor cell migration and metastasis. *Cancer Cell* 15, 124-134.

Zhang, X., Yu, L., and Xu, H. (2016). Lysosome calcium in ROS regulation of autophagy. *Autophagy* 12, 1954-1955.

Zhao, H., Li, T., Wang, K., Zhao, F., Chen, J., Xu, G., Zhao, J., Li, T., Chen, L., Li, L., *et al.* (2019). AMPK-mediated activation of MCU stimulates mitochondrial Ca<sup>2+</sup> entry to promote mitotic progression. *Nat Cell Biol* *21*, 476-486.

Zhong, F., Harr, M. W., Bultynck, G., Monaco, G., Parys, J. B., De Smedt, H., Rong, Y. P., Molitoris, J. K., Lam, M., Ryder, C., *et al.* (2011). Induction of Ca<sup>2+</sup>-driven apoptosis in chronic lymphocytic leukemia cells by peptide-mediated disruption of Bcl-2-IP3 receptor interaction. *Blood* *117*, 2924-2934.

Zurborg, S., Yurgionas, B., Jira, J. A., Caspani, O., and Heppenstall, P. A. (2007). Direct activation of the ion channel TRPA1 by Ca<sup>2+</sup>. *Nat Neurosci* *10*, 277-279.

**A****Ca<sup>2+</sup> signalling ON****B****Ca<sup>2+</sup> signalling OFF****Figure 1**




Figure 2




Figure 3




Figure 4




Figure 5